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The transport mechanisms of secretory and endocytic pathways are 
responsible for the coordinated movement of proteins and lipids throughout 
the cell at the proper time and place.  In mammalian cells, there are many 
proteins dedicated to maintaining organelles and the trafficking of materials 
between them, though the mechanisms that regulate these processes are far 
from being fully understood.  For over a decade, the role of phospholipase 
and acyltransferase lipid-modifying enzymes in membrane trafficking has 
been described, but the identity of the proteins involved had not been 
determined.  Inhibitor studies demonstrated that both PLA2 and LPAT 
enzymes regulate trafficking events and membrane tubule formation from the 
Golgi complex and endosomes.  In the last year, one LPAT and three PLA 
enzymes were found to contribute to trafficking and organelle maintenance of 
the Golgi and endosomes, including the work described here.  
The function of the PLA2 enzyme complex platelet activating factor 
acetylhydrolase Ib (PAFAH Ib) was investigated at both the Golgi complex 
and endosomes.  Employing overexpression and knockdown of PAFAH Ib 
subunits in mammalian cells, I have found that the catalytic α subunits and 
the non-catalytic β subunit, LIS1, are important for the maintenance of an 
intact Golgi ribbon.  The catalytic α subunits are important for the formation 
of membrane tubules and anterograde trafficking.  I have also found that each 
 α subunit has distinct contributions to regulating Golgi morphology, 
assembly, and secretory trafficking.  Knockdown of one subunit alone is not 
compensated by the presence of the other.  At endosomes, both α subunits are 
important for membrane tubule formation and endocytic recycling pathways.  
Furthermore, the interaction of these subunits with LIS1 appears to regulate 
the distribution of endocytic compartments within the cell. 
Additionally, I have used an in vitro Golgi membrane tubule 
reconstitution assay to investigate the regulation of membrane tubule 
formation by heterotrimeric Gβγ subunits.  I utilized inhibitors of PLA2 
enzymes and the purified Gβ1γ2 protein complex to demonstrate that Gβ1γ2 
can stimulate Golgi membrane tubules through a PLA2 dependant pathway.  
This suggests that Gβ1γ2 may regulate the activity of PLA2 enzymes important 
for the formation of membrane tubules or positive membrane curvature.  
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CHAPTER 1 
General Introduction 
 
For every organism, the coordinated movement of macromolecules 
within the cell is a constant and critical part of life.  Eukaryotic cells are 
physically compartmentalized to enclose components for particular metabolic 
pathways within membrane-bound organelles, including: the nucleus, 
mitochondria, peroxisomes, lipid droplets, the endoplasmic reticulum, the 
Golgi complex, endosomes, and lysosomes.  Many macromolecules—e.g. 
proteins, lipids, carbohydrates, DNA, etc.—require a specific environment and 
localization to properly function.  If a protein involved in transport of 
nutrients across the plasma membrane is misrouted to any other location it 
could be devastating to cell homeostasis.  Additionally, the transport of lipids 
is essential for all cells.  Lipid trafficking is particularly critical in specialized 
cells, such as Schwann cells, which insulate the electrical signals of neurons by 
producing massive membrane sheets that wrap vertebrate neurons in the form 
of a myelin sheath.  Eukaryotic cells have developed tightly regulated spatial 
and temporal trafficking mechanisms to permit cellular processes to become 
more complex and specialized. 
 
The Secretory Pathway 
An estimated one quarter to one third of proteins encoded in the 
human genome are synthesized at the endoplasmic reticulum (ER) and 
shuttled through the secretory pathway (1), as depicted in Figure 1-1.  Newly 
synthesized proteins in the rough ER and lipids from the smooth ER are 
packaged and delivered to the Golgi complex, traverse the Golgi stack to the  
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Figure 1-1:  A depiction of the secretory and endocytic organelles and related 
trafficking pathways.  Transport intermediates carrying both proteins and 
lipids between the membrane bound organelles occurs via various membrane 
bound vesicles—COPI, COPII, clathrin (AP-1 or AP-2)—or membrane tubules.  
Microtubule motor proteins are shown (dynein and kinesin) at respective 
transport steps.  Red arrows indicate transport that can occur by membrane 
tubules.  TGN = trans Golgi network, RER = rough endoplasmic reticulum,  
VTC = vesicular tubular cluster, ERGIC = ER-Golgi-Intermediate 
Compartment, MVB = multivesicular body. 
 3 
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trans Golgi network (TGN), where they are sorted and packaged for delivery 
to their site of function outside the cell, on the plasma membrane, in 
endosomes, or in lysosomes.  Since the first description of the secretory 
pathway by George Palade (2), there have been many advances in our 
understanding of how proteins and lipids are sorted and shuttled through 
these organelles, but many details and regulatory mechanisms have yet to be 
revealed.   
 
Endoplasmic Reticulum 
The endoplasmic reticulum (ER) is an expansive organelle of 
membrane sheets and a tubular network reaching from the nuclear envelope 
to the outer edges of mammalian cells (3).  The mRNA of transmembrane or 
luminal proteins destined for the secretory pathway initially begin translation 
in the cytoplasm and are quickly recognized and shuttled to the surface of the 
rough ER by the signal recognition particle, which recognizes a signal 
sequence on the nascent polypeptide as it is generated by an associated 
ribosome (4).  Upon reaching the ER, the polypeptide chain is co-
translationally directed into the lumen or membrane of the ER by the 
translocon.  The process of nascent chain recognition and ER insertion is 
reviewed in (4-6).  Upon arrival in the ER, an assortment of chaperone 
proteins aid in proper protein folding, disulfide isomerases assist in correctly 
forming disulfide bonds, and resident glycosylation enzymes modify the 
proteins.  Once properly folded, these proteins are targeted for packaging into 
membrane-bound vesicles that bud from specific ribosome-free subdomains of 
the ER known as ER exit sites (ERES) (7, 8).   
The smooth ER is a major site of cell membrane biosynthesis, 
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containing many of the enzymes that convert storage lipids (such as 
triacylglycerol, TAG) into certain types of glycerophospholipids.  Lipids 
generated in the ER additionally must exit the ER and progress to the Golgi 
complex.  These membrane lipids can undergo movement to the Golgi 
complex either in membrane-bound transport intermediates or are shuttled by 
specific transfer proteins (e.g. CERT, FAPP2) to the Golgi and TGN, as is the 
case for lipids such as ceramide (9). 
At ERES, a specific set of proteins has been identified that regulate 
sorting of cargo into membrane buds and form spherical vesicles.  Several of 
these proteins, known as coat protein complex II (COP II) components, bind to 
transmembrane cargo and coat the surface of budding ER membranes (10-12).  
COPII coated vesicles shed their coat shortly after budding, allowing the 
vesicles to fuse with other membranes that form vesicular tubular clusters 
(VTC), structures also known as the ER Golgi Intermediate Compartment 
(ERGIC), that are shuttled to the Golgi complex (13-19).   
 While exported proteins and lipids progress to the Golgi complex (i.e. 
move in an anterograde direction), ER resident proteins that escape are 
captured and retrieved by specific receptors, such as the KDEL receptor at the 
ERGIC compartment as well as early Golgi compartments (i.e. move in an 
retrograde direction).  These receptors recognize specific amino acid 
sequences, such as KDEL (20), that act as ER retention signal sequences for 
their retrieval back to the ER.  The process of sorting these ER proteins for 
retrieval is aided by the subsequent packaging of KDEL receptors by another 
class of coat proteins that are part of the coat protein complex I (COPI) (20-24).  
In addition to these spherical vesicle transport carriers, proteins and lipids 
returned to the ER by this retrograde pathway can be seen to move through 
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long membrane extensions known as membrane tubules (21, 25-27).  The 
sorting and packaging of both anterograde and retrograde cargo into vesicles 
at the ER and Golgi interface is also reviewed in (1).  Once arriving at the 
ERGIC, proteins and lipids are transported to the anterograde ‘arrival center’ 
of the Golgi complex, the cis cisternae of the Golgi complex.  While some 
evidence suggests that COPI may be involved in anterograde transport from 
the ERGIC to the cis Golgi (28), the ERGIC is alternatively thought to grow 
and mature into or fuse with the cis cisternae of the Golgi complex, thereby 
moving cargo forward as ER proteins are packaged by COPI and returned to 
the ER (14, 18, 29, 30).  
 
The Golgi Complex 
The Golgi complex is believed to be the central hub of trafficking in 
mammalian cells, critical for processing and sorting newly synthesized lipids 
and proteins from the ER to endosomes, lysosomes, the ER, the plasma 
membrane and out of the cell.  At the same time, the Golgi complex also 
receives lipids and proteins from endosomes.  As cargo from the ER passes 
through the stacked/layered membrane subdomains called cisternae in an 
anterograde direction (cis to trans), they are exposed to unique enzymes, 
decreasing pH, and changes in lipid compositions (e.g. increasing cholesterol 
and sphingolipids) (31-35).  The realization that the Golgi complex is the major 
site of protein glycosylation (36) led to the discovery that unique subdomains 
in the Golgi complex exist.  The Golgi cisternae cis, medial, trans, and the TGN, 
each have sequential glycosylating enzymes and lipid metabolism enzymes 
that are resident to that compartment (37-40).    
Constant departure and arrival of proteins and lipids creates a complex 
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organelle architecture that is highly fenestrated with numerous vesicles and 
tubules on both the cis and trans most sides of the Golgi complex (13, 41-44).  
In between the outermost cisternae, relatively compact membrane stacks of cis, 
medial, and trans cisternae are present, often bridged into a ribbon-like 
structure with membrane tubules between and across cisternae (45-49).  
Numerous vesicles have been seen emanating from less compact regions 
within the Golgi complex (50).  
The Golgi ribbon structure is seen in most animal cells, however in 
plants, Drosophila, and certain yeast species such as Schizosaccharomyces pombe 
and Pichia pastoris the Golgi complexes are mini-stacks, physically separate 
and distributed throughout a cell rather than in a centralized Golgi ribbon (51-
54).  Strikingly, the number of cisternae within a cell remains constant, but 
between cells and cell types this number varies (35).  Most animal cells have a 
total of 3-8 individual cisternae, whereas plant cells can exceed 100 (35, 53).  
Another deviation in Golgi structure is found in the yeast Saccharomyces 
cerevisae, which do not have stacked Golgi and have separated cisternae 
scattered throughout the cell (51, 54).  It is unclear if a stacked or ribbon 
structure is important for enzymatic function or transport and whether the 
Golgi complex structure found in mammalian cells has evolved to become 
more efficient to accommodate increasingly complex or extensive trafficking. 
A more detailed review of Golgi evolution in eukaryotes can be found in (55).  
In mammalian cells, the Golgi complex structure is maintained by the 
constant flux of proteins and lipids, tethering proteins, as well as microtubule 
and dynein-dependent anchoring to the centrosome (the convergence point 
for the minus ends of radial-positioned microtubules).  The Golgi cisternae 
may vary greatly in volume, expanding or shrinking accordant to the 
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flux/secretory load of proteins and lipids through the Golgi complex (56-58).  
The tethering, protein-dense meshwork surrounding the Golgi (aka Golgi 
matrix) (59-62) is maintained by golgins (reviewed by (63)), which bind to 
cisternae and vesicle membranes, keeping cisternae as a stacked structure and 
aiding in the capture of vesicles.  The mammalian Golgi complex is held close 
to the centrosome (within 1-3 µm) by the microtubule motor dynein (35, 64-
66).  Dynein and microtubules are important for maintenance and the 
formation of Golgi ribbon structure (64, 67, 68).  
During mitosis the Golgi complex disassembles, either redistributing its 
contents to the ER (69-73) or becoming fragmented and scattered upon the 
disassembly of the microtubule network (74-77).  After cell division, the Golgi 
first appears as small, distinct stacked cisternal units, mini-stacks, that are 
disconnected and scattered throughout the cell.  These mini-stacks eventually 
converge into a single stacked Golgi complex located adjacent to the 
centrosome.  This process has been shown to be dependent on microtubules 
and involves the microtubule motor dynein (67, 75).  The reassembly of the 
Golgi and continual maintenance of Golgi ribbon structure are also dependent 
on membrane tubules (78, 79).   
Transport through the Golgi (intra-Golgi transport) has been a topic of 
debate for many years.  Several models exist to address how cargo moves 
forward while the enzyme and lipid compositions of cisternal sub-
compartments is maintained.  The two primary models, cisternal maturation 
model and vesicular transport model, suggest that either the cisternae itself 
carries cargo forward while enzymes are recycled back, or the cargo is 
packaged into transport carriers that move forward while enzymes stay in 
distinct cisternae (80, 81).  Much of the argument lies in the inconsistencies 
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between studies (82-84), such as reports that COPI vesicles contain Golgi 
resident enzymes (23, 85), while other reports suggest that COPI vesicles 
contain secretory cargo and not resident enzymes (86, 87).  The predominant 
model of the field is that of cisternal maturation: the ERGIC matures into the 
cis Golgi, which matures into medial, trans and then peels away from the Golgi 
stack turning into the TGN, which is consumed by the creation of transport 
vesicles and tubules (88, 89).  In this model, COPI vesicles (or membrane 
tubules) would recycle enzymes to newer cisternae.  Recent work using live 
imaging of fluorescently tagged cargo and distinct cisternae resident enzymes 
in S. cerevisiae showed that resident enzymes rapidly change from cis, medial, 
to trans in each cisterna spot (90, 91).  These results indicate that a cisterna 
acquires the next set of enzymes from a more ‘mature’ cisterna, strongly 
supporting the maturation model.  The cisternal maturation model is also 
supported by the movement of pro-collagen and algae scales through the 
Golgi stack.  These molecules stay within the cisternae as they traverse the 
Golgi complex (92, 93).  Other models, besides cisternal maturation and the 
vesicular transport model, suggest that compartments of the Golgi are not 
always distinct, and tubules interconnect cisternae to provide a route for cargo 
to progress forward or enzymes to be transferred to new cisternae (47).  A new 
and controversial model of ‘rapid-partitioning’ suggests that cargo and 
enzymes separate/partition laterally across cisternae (94).  This model 
accounts for the kinetics of cargo transport seen in live-cell imaging studies, 
which are not consistent with the maturation model, and addresses disputes 
on the direction of movement for enzymes in transport carriers, indicating the 
carriers are bidirectional.  This model also incorporates the role of lipids in 
sorting and partitioning transmembrane proteins.  However, the rapid 
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partitioning model is difficult to reconcile with the foundation that resident 
enzymes are enriched in particular cisternae and are in sequential order to 
which glycosylation reactions take place (33).  A more comprehensive 
discussion of recent work on transport through the Golgi complex can be 
found in (95). 
Irrespective of the exact route for cargo to be modified and traverse the 
Golgi complex, proteins and lipids requiring export from the Golgi complex to 
the plasma membrane and endosomes reach the TGN.  The TGN is considered 
the major sorting and packaging site for cargo traversing the Golgi complex.  
The TGN additionally receives proteins and lipids transported from 
endosomes, a process that is believed necessary for the homeostasis of the 
TGN.  The gradual anterograde enrichment of particular proteins and lipids 
across the Golgi stack combined with the arrival of lipids and proteins from 
endosomes creates a distinct TGN composition rich in cholesterol, 
sphingolipids, and enriched in enzymes for the synthesis of sphingomyelin 
(96, 97).  
At the TGN, it is believed that sorting can occur through the formation 
of lipid domains and cargo segregation by vesicle coat proteins.  The TGN 
sorts and packages cargo for delivery to endosomes using a particular class of 
vesicle coat proteins known as clathrin and clathrin adaptor proteins (96-98).  
At the TGN, both AP1 and GGA (Golgi-localized, γ-ear-containing, ADP-
ribosylation factor-binding proteins) clathrin adaptor proteins recognize cargo 
for transport to the endocytic/lysosomal system.  Endosome/lysosome 
destined cargo are believed to contain sorting signals that aid in their 
recognition and packaging into endosome-destined clathrin coated vesicles 
(99).  Sorting events at the TGN are also important for segregation of cargo 
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destined for apical versus basolateral membranes in polarized cells, reviewed 
in (100-102).  One example of TGN sorting in polarized cells is through the use 
of the clathrin adaptor AP1B, which may recognize sorting signals within the 
cargo for packaging into basolateral-destined vesicles (102-106).   
Other cargo destined for the plasma membrane is found in clathrin-
independent transport carriers: secretory granules for regulated secretion, 
non-clathrin or -COP coated vesicles, and larger tubular carriers.  The 
mechanisms for selective cargo transport from these alternative transport 
carriers are not well understood.  The tubular carriers do not appear to 
concentrate cargo at the TGN and are thought to allow for bulk, constitutive 
secretion (107-109).  However, membrane tubules seen at the TGN exclude 
resident enzymes, suggesting some level of segregation exists (108, 110).  
Cargo segregation may be partly controlled by the partitioning of cholesterol 
and sphingolipids into domains on the TGN membrane, which has been 
suggested for glycosylphosphatidylinositol (GPI)-anchored protein transport 
to the apical plasma membrane (111, 112).  Further discussion of TGN exit 
mechanisms can be found in (96, 97). 
 
Endocytic Trafficking Pathways 
 Cell surface proteins and material internalized into a eukaryotic cell is 
often packaged into small inward-budding vesicles at the plasma membrane.  
Once budded into the cell, the nutrients, proteins, and lipids are delivered to 
sorting stations known as early sorting endosomes, where machinery further 
packages the material for degradation in the lysosome or recycling back to the 
plasma membrane (113).  The endocytic pathway is depicted in Figure 1-1.  
Mammalian cells internalize their entire plasma membrane contents once 
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every 1-5 hours, therefore it is critical that a balance of internalization, 
delivery, and recycling exists (114).  
Like most organelles, the types of endocytic organelles are defined by 
enriched proteins and lipids that compose them.  However, the composition of 
endosomes is dynamic, and the presence of lipids and proteins is continually 
changing (115, 116).  Therefore the classification of endosomes based on the 
presence of different protein and lipid components only identifies a transient 
stage of endocytic organelles.  Endosomes are constantly sorting, enriching, 
and exchanging molecules with other membrane bound compartments and 
the cytoplasm.  
Proteins and lipids to be endocytosed are segregated prior to 
internalization.  Particular types of cargo are internalized in specific plasma 
membrane domains and by specific sets of machinery.  These endocytic 
processes are subdivided into clathrin-dependent and clathrin-independent, 
which includes caveolae, phagocytosis, pinocytosis and other membrane 
invaginations.  Endocytic events are extensively reviewed in (117, 118).  
Clathrin-mediated endocytosis is the best understood route of endocytosis, 
involving recognition of dileucine and tyrosine-based sorting signals/motifs 
in plasma membrane receptors by clathrin adaptor AP2 (99).  
Vesicles and tubular invaginations from the plasma membrane fuse 
with each other and with early sorting endosome membranes, which are 
occupied sequentially with components involved in regulating fusion, sorting 
of cargo, and budding of cargo (116, 119, 120).  Early endosomes are defined 
as the receiving compartments for plasma membrane internalized cargo.  
These compartments are enriched in specific Rab GTPases, Rab5 and Rab4, 
which are involved in regulating the fusion and transport of cargo from the 
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plasma membrane and delivery to the endocytic recycling compartment 
(ERC), respectively (115, 119, 121, 122).  Early endosomes are also enriched in 
proteins and lipids involved in the recruitment of fusion and sorting 
machinery, upstream and downstream of Rab protein recruitment and 
activation, such as the phosphoinositide-3-P kinase (PI(3)P kinase), the 
phosphoinositide-3-phosphate (PI(3)P), and EEA1 (early endosome antigen 1, 
a Rab5 effector protein) (119, 123).  
The predominant model for endocytic sorting is through a process of 
endosome maturation.  Membrane tubules sort away cargo destined for the 
recycling pathway at early endosomes, while cargo to be degraded remains in 
early endosomes as the endosomes change their composition by recruitment 
of proteins from the cytosol and ‘kiss-and-run’ or fusion events with other 
endocytic compartments to gradually exchange early endosome proteins for 
late endosome machinery (119, 122, 124, 125).  Early endosome membrane 
tubules have been shown to concentrate or sort transmembrane proteins and 
lipids away from soluble, luminal cargo (126, 127).  This process occurs as the 
endosomes move on dynein motors towards the minus end of microtubule 
tracks (116, 128, 129).  Concomitantly, transmembrane proteins that are 
destined for degradation are tagged with ubiquitin and recognized by Hrs and 
ESCRT (endosome sorting complex required for transport) machinery that 
sorts these proteins into invaginating domains on the endosome (130-134).  
These domains eventually turn into small inward budding vesicles enriched in 
the lipid lysobisphosphatidic acid (bis(monoacylglycero)phosphate) and bud 
into the lumen of an endosome, which can be seen in late endosome multi-
vesicular bodies (MVBs) (120, 135, 136).  These endosomes mature into late 
endosomes or MVBs by losing early endosome components and acquiring late 
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endosome proteins and lipids such as Rab7, Rab9, CD63, PI(3,5)P (by 
phosphoinositide kinase PIKFyve activity) (119, 137-139).  They also increase 
amount of vacuolar H+-ATPase pumps that lower the pH from ~6 to pH ~5 
and receive lysosomal hydrolases delivered from the TGN (122, 140).  Further 
enrichment of LAMPs (lysosomal associated membrane proteins), acquisition 
of lysosomal enzymes, and decrease in pH down to pH 4-5 occurs as late 
endosomes and MVBs merge with lysosomes, the terminal destination for 
cargo to be degraded (122, 140-142).  The low pH activates hydrolases that 
degrade the luminal soluble and internal vesicles at the lysosome.   
 Cargo destined for recycling to the plasma membrane can travel 
directly from early endosomes to the plasma membrane in a ‘rapid/short’ 
recycling pathway (143, 144), but it is believed that the majority of recycled 
components travel from the early sorting endosomes to the ERC.  The actual 
fraction of cargo traveling in the short recycling versus the ‘long,’ ERC-
mediated pathway is not known (115).  Proteins involved in the regulation of 
endocytic recycling pathways can be found reviewed in more detail in (121).  
The vast majority of recycled cargo can be seen traveling from early 
endosomes to the ERC by membrane tubules (113, 145).  Upon reaching the 
ERC, which is a more stationary tubulovesicular network often adjacent to the 
TGN, cargo is sorted to the plasma membrane in membrane tubule carriers 
(115, 146).  In polarized cells, the ERC may play a pivotal role in transcytosis 
and the regulation of sorting apical versus basolateral cargo to the correct 
plasma membrane surface (100, 147).  The transport of cargo from the ERC to 
the plasma membrane is regulated by Rab11 and EHD/RME1 (Eps15-
homology-domain protein/receptor-mediated endocytosis protein) (115, 121).  
Rab11 is the most common marker for the ERC due to its fairly stable 
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association with these membranes.  Both EHD family members and sorting 
nexins (SNX) have been shown to be involved at specific endocytic transport 
steps, and both families have been shown to either stimulate or stabilize 
membrane tubules from endocytic compartments (121, 148-150). 
 As previously mentioned, there are also retrograde pathways from 
endosomes to the TGN that aid in recycling membrane and proteins required 
for TGN functions. One such pathway is mediated by the retromer complex, 
which forms either vesicles or tubules from endosomes (early to late) that 
move from these endosomes to the TGN (151-154).  The retromer complex aids 
in recycling TGN-based proteins such as the mannose-6-phosphate receptor 
(M6PR), so it may be used for additional rounds of transport from the TGN to 
the endocytic pathway.  The retrograde endosome-to-TGN pathway is 
reviewed in (152, 155).  Additional reviews on endocytic trafficking pathways 
can be found in (115, 121, 122, 152, 156). 
 
Transport Carriers: Vesicles and Membrane Tubules 
While both membrane bound vesicles and membrane tubules have 
been seen emanating from organelles of the secretory and endocytic 
pathways, it is still unclear what the relative contributions are of these two 
types of cargo carriers.  These transport carriers exist at the ER, Golgi complex, 
and endosomes and aid in the sorting of cargo by both lipid-based and 
protein-based mechanisms (24, 157-159).  Each of these carriers bud from a 
donor membrane, travel along cytoskeletal tracks, and then fuse with the 
target organelle for proper delivery.  General mechanisms fundamental to this 
process can be found reviewed by (24, 160). 
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Vesicles 
Vesicles were originally hypothesized to be the major route of protein 
trafficking between organelles, starting from the early studies of the secretory 
pathway by George Palade (2).  Shortly after these studies the first vesicle coat 
protein, clathrin, was purified (161).  Much has been revealed about the 
molecular mechanisms of vesicular transport in the 30 years since the initial 
vesicle transport hypothesis and the identification of clathrin, including 
mechanisms of vesicle formation, fission, targeting, and fusion.  A 
temperature-sensitive yeast mutant screen by the Scheckman lab was a pivotal 
point in the identification of specific proteins involved in the secretory 
pathway.  These proteins were coined ‘Sec’ proteins (162, 163).  Studies by the 
Rothman lab using an in vitro reconstitution system and biochemical 
approach identified the contribution of key proteins such as COPI and 
SNAREs in transport (24, 164-166).  These initial studies led to a large 
expansion of research into the mechanisms of vesicle-mediated transport in 
cells.   
There are three main types of coated vesicles in mammals: COPI, COPII, 
and clathrin.  Each of these types of coated vesicles requires protein complexes 
for their assembly and budding.  The COPII, COPI, and clathrin coats are 
multi-subunit complexes containing proteins that bind to cargo and form 
cage-like scaffolding believed to aid in inducing membrane curvature (12, 160, 
167).  These vesicles bud from membranes, load onto cytoskeletal tracks by 
motor proteins, shed their protein coat, dock to the receiving membrane 
through tether proteins and SNARE machinery, and then fuse with the target 
membrane (24, 160, 166).  Many of these steps, including that of initial 
assembly, uncoating, docking, and fusion are regulated by small GTPases 
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(such as Sar1, Arf1, and Rabs) that aid in the recruitment of proteins involved 
in each of these processes or by directly interacting with vesicle machinery 
(24).  The selectivity of transport for these vesicles is believed to partially lie in 
the particular coat proteins used to form the vesicles.  Clathrin coated vesicles 
associate with particular adaptor protein complexes (AP1, AP2, AP3 or GGA), 
which are found on vesicles budding from and transported to specific 
membranes.  For example, AP2 adaptor proteins are specifically found at the 
plasma membrane and involved in clathrin-mediated endocytosis (160).  The 
AP1 and GGA subunits are associated with clathrin at the TGN for transport 
to late endosomes.  AP1 subunits recognize tyrosine-based sorting signals 
(such as YXXØ) in cargo and GGAs assist in sorting the M6PR through acidic 
clustered dileucine motifs (99).  Similarly, coatamer complexes have recently 
been acknowledged to contain isoforms of subunits that can be found in 
distinct vesicles.  For example, particular COPII Sec24 isoforms have been 
found to localize with specific subsets of cargo molecules (168-170).  COPI 
subunit isoforms have been implicated in forming distinct vesicles at different 
locations within the Golgi complex (171). 
 
Membrane Tubules 
Electron microscopy studies long ago noted long membrane extensions, 
60-100 nm in diameter, from organelles (41, 48, 49, 172-175), but these 
structures were not recognized as a mode of transport between organelles 
until live-cell imaging studies of fluorescent proteins and lipids.  Initially, 
studies of the fungal metabolite brefeldin A (BFA) demonstrated dramatic 
tubule formation, carrying Golgi resident enzymes in a retrograde direction to 
the ER (176).  The belief that vesicles were the sole transport carrier in 
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membrane trafficking changed when real time, live-cell imaging of transport 
intermediates containing green fluorescent protein (GFP)-tagged proteins and 
fluorescent lipids revealed the presence of long, thin membrane extensions 
that protrude from organelles, extend, break off and fuse with other organelles 
(177-182).  These results showed that membrane tubules were not restricted to 
the presence of BFA and that membrane tubules appear to carry cargo (179-
181, 183).  Additionally, membrane tubules have been seen to occur regardless 
of vesicle inhibition by BFA or RNAi of vesicle components (180, 184) and 
exist with or without accompanying budding vesicles (180, 185, 186).   
Like vesicles, tubules require an initial outward protrusion and 
extension from the donor membrane of an organelle, fission from the donor 
membrane, linkage to motor proteins and the cytoskeleton (which they have 
been shown to move along) (177, 178), and eventual fusion with the target 
compartment (158).  Membrane tubules have been proposed to contribute to 
the sorting of protein and lipid cargo at many steps of trafficking: cis to trans 
intra Golgi transport (47), retrograde cargo trafficking to the ER (26, 178, 180, 
187), ER to Golgi transport (11, 16, 179, 183, 188), TGN to cell surface 
trafficking (181, 185, 186, 189), and in endocytic recycling pathways (113, 115, 
145, 152, 190).  Additionally, endocytic cargo is shown to be concentrated 
within tubules (126, 191-193), likely from sorting of protein and lipid cargo via 
the tubule shape, which increases the membrane to lumen ratio (194-196).  
These observations suggest that tubules are a distinct and cooperative 
component of sorting and trafficking.  The mechanisms of formation and 
regulation of these transport carriers are only now beginning to be identified.   
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Transport Intermediates: Bending a Membrane 
To shuttle proteins and lipids between the various organelles of the 
secretory and endocytic pathway, domains on organelle membranes must first 
bend into spherical and tubular shapes to create vesicles and tubules, which 
then undergo constriction/pinching for their fission and release.  This bulging 
and constriction may be achieved by several means: proteins that bind to the 
membrane surface and generate forces that bend, stretch, and pinch off the 
carriers, proteins that insert into membranes, or via changes in the lipid 
composition of the membrane itself.  These mechanisms are reviewed in (167).   
Proteins can generate force to bend membranes in a number of ways.  
Linking motor proteins to membranes can generate force to pull or stretch the 
membrane; the kinesin motor protein has been shown to pull tubes from giant 
unilamellar vesicles (GUVs) in vitro (197).  Many proteins have been 
implicated in bending membranes by forming scaffolds that force the 
membrane to adopt their particular shape (167).  For example, proteins of 
coated vesicles, such as COPII, form curved, cage-like scaffolding that may 
contribute to the bending energy needed to form vesicles (167, 198-200).  
Certain BAR-domain containing proteins, such as SNXs, have an intrinsic 
crescent-shaped structure and dramatic tubulation of membranes occurs when 
these proteins are overexpressed in cells or with liposomes in vitro (148, 198, 
201-204).  However, it is unclear whether these SNXs and other BAR-domain 
containing proteins induce the curvature or stabilize curvature that already 
exists, as they preferably bind to curved membranes and form scaffolds on 
their surfaces (201, 205-208).    
Membrane curvature can also be achieved by the insertion of 
amphipatheic or hydrophobic regions of proteins, such as caveolin, reticulons, 
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Arf1, Sar1 and certain BAR domain containing proteins, into the outer leaflet 
of the membrane bilayer (12, 167, 209-212).  Many of these proteins have been 
shown to generate tubules from liposomes in vitro in addition to being 
important for membrane trafficking events, vesicle, and/or membrane tubule 
formation in cells (213-216).  Changes in membrane composition on one leaflet 
of the membrane bilayer can generate changes in membrane curvature.  This 
membrane bilayer couple hypothesis was proposed by Sheetz and Singer in 
the 1970s (217) and has progressed over the years to aid in understanding how 
membrane bilayer asymmetry can generate membrane curvature.  
The lipid composition itself also has a fundamental role in providing 
the framework for membrane bending, fission and fusion (159, 198, 218, 219).  
Lipids can contribute in several ways, by changing the fluidity/rigidity of the 
membrane, making it easier or more difficult to stretch, bend and push the 
bilayer, by generating an intrinsic curvature, or by creating domains that 
allow for regulatory protein binding.  Specific lysophospholipids (LPLs), 
phosphatidic acid (PA), and diacylglycerol (DAG) all have spontaneous 
(intrinsic) positive or negative curvature that can bend membranes as well as 
increase or decrease fusion and fission events (198, 220, 221).  Several lipid 
species have been shown to recruit effector proteins to membranes, such as 
DAG, which recruits fission factors such as protein kinase D (PKD) (222).  
Another well-studied class of lipid signaling/targeted binding molecules is 
phosphoinositides.  Phosphoinositol (PI) can be phosphorylated at several 
specific points in the inositol ring, allowing for several phosphoinositol 
phosphate (PIPs) species.  These PIPs have been shown to be enriched in 
specific organelle membranes and therefore contribute to organelle ‘identity’, 
allowing for proteins to specifically bind to one organelle membrane and not 
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others (223-226).  PI(4,5)P2 and PI(3,4,5)P3 are enriched at the plasma 
membrane, PI(3)P on early endosomes, PI(4)P at the Golgi or TGN, and 
PI(3,5)P at late endosomes (227).  
 
Regulation of Membrane Trafficking by Lipid Composition 
There is growing realization that lipids can have a dramatic impact on 
the behavior of proteins, protein recruitment to membrane surfaces, and the 
formation transport intermediates (159, 210).  Lipid composition has been 
shown to create environments that proteins can partition into or exclude 
themselves from, generate binding surfaces to recruit effector proteins 
involved in regulation of trafficking, or change intrinsic curvature to aid in 
membrane bending, fission, and fusion (159, 219-221).  Additionally, 
asymmetric changes in membrane composition can generate changes in 
membrane curvature (217).  Thus, lipid-modifying enzymes are crucial to 
intracellular trafficking.  Many phospholipid-modifying enzymes exist in 
mammals to create an enormous variety of phospholipid species with varying 
head groups, acyl chains, and covalent bonds between the fatty acid chains 
and glycerol.  The membrane composition—the specific phospholipids, fatty 
acids, and sterol content—can have a profound effect on the fluidity/rigidity, 
curvature, and binding affinity for proteins (159); all of which regulate 
organelle architecture and membrane trafficking.  Several general classes of 
proteins contribute to generating membrane bilayer asymmetry in the bilayer, 
including lipases and acyltransferases—both of which directly alter individual 
phospholipids—as well as flippases which can move phospholipid species 
between the two leaflets.   
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Lipid-modifying Enzymes 
 Several classes of phospholipid altering enzymes have been implicated in 
organelle architecture and membrane trafficking, particularly phospholipases 
and acyltransferases, which cleave or reacylate phospholipids as depicted in 
Figure 1-2.  Phospholipase C member PLCβ3 was implicated in TGN to 
plasma membrane transport by generation of DAG, which recruits the fission 
factor PKD (228).  Phopshoinositide lipids (PIs, PI(4,5)P2 and PI(4)P) are 
cleaved by specific PLC enzymes to generate DAG, which is a negative 
curvature inducing PL that also recruits fission factors such as PKD to the 
TGN (220, 222, 229, 230).  Phospholipase D (PLD) has been shown to generate 
DAG indirectly by converting PC to PA, which can then be converted into 
DAG by lipid phosphate phosphatase (LPP).  Both PLD1 and PLD2 are 
thought to partially localize to Golgi membranes (231, 232) and in vitro 
increase secretory vesicle release from Golgi membranes (233).  PLD2 has also 
been implicated in endocytic recycling transport carrier formation (234, 235).  
Cells with reduced PLD levels show decreased export of secretory cargo, 
specifically CFTR (cystic fibrosis transmembrane conductance regulator) (236) 
and inhibition of PLD by 1-butanol shows decreased VSV-G trafficking both 
the ER to Golgi and TGN to plasma membrane, as well as altering Golgi 
complex structure (237). Further review of PLD and the Golgi complex can be 
found in (238).   
 The generation of PA by the lysophospholipid acyltransferase (LPAT, 
AGPAT) AGPAT3 was shown to be important for Golgi architecture and 
Golgi membrane trafficking (239).  PA is also a negative curvature inducing 
PL and is critical for membrane trafficking events through its intrinsic 
negative curvature-promoting shape (220, 229, 230) or by the conversion of PA  
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Figure 1-2:  Role of lipid-modifying enzymes.  (A) Simplified phospholipid 
metabolism pathways pertinent to trafficking and structures of the lipids 
involved are shown (based on (250)).  PC = phosphatidylcholine, LPC= 
lysophosphatidylcholine, PA = phosphatidic acid, LPA= lysophosphatidic 
acid, DAG = diacylglycerol, PI(4)P = phosphatidylinositol 4-phosphate, PLC = 
phospholipase C, PLD = Phospholipase D, DAGK = DAG kinase, LPP = lipid 
phosphate phosphatase, PLA = phospholipase A, LPAT = lysophospholipid 
acyltransferase. (B) Putative roles for PLA and LPAT enzymes in generating 
membrane curvature.  PLA enzymes remove an acyl chain (fatty acid, FA) 
from phospholipids (PL), generating an inverted cone shaped 
lysophospholipid (LPL).  LPAT enzymes can reacylate LPA, generating PA, a 
cone-shape, negative curvature inducing PL. 
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to DAG (230, 240, 241) (Figure 1-2).   
 Phospholipase A (PLA) enzymes have also been implicated in generating 
shape changes in phospholipids to induce positive curvature in membranes 
(242).  PLA enzymes are divided into PLA1 and PLA2, designated as such for 
the fatty acyl chain cleaved from the phospholipids, either from the sn-1 or sn-
2 position, respectively.  PLA hydrolysis of phospholipids to generate 
lysophospholipids may change the shape of PLs from a cylindrical shape to an 
inverted-cone shape LPL.  The local generation of lysophospholipids on the 
cytosolic leaflet of membranes would change the shape of the membrane (217, 
242), depicted in Figure 1-2.  Such a change in local phospholipids has been 
demonstrated by treating erythrocyte membranes with a PLA2, yielding 
numerous membrane protrusions (243).  In contrast, reversing outward 
curvature or inducing negative/inward curvature has been hypothesized to 
occur by the action of LPAT enzymes as described above. 
 A number of studies have suggested that PLA enzymes are important for 
membrane tubule formation at the Golgi complex and endosomes.  A 
pharmacological screen of enzyme antagonists found that cytosolic PLA2 
inhibitors abolished BFA-stimulated tubules from Golgi and endosomes in 
vivo as well as cytosol-stimulated tubules from isolated Golgi and endosomes 
in an in vitro reconstitution assay (244, 245) (Figure 1-1).  It was further 
demonstrated that LPL and FA chain products from PLA2 activity are 
primarily responsible for the generation of these membrane tubules, as 
arachidonic acid and other downstream metabolites of LPLs and FAs were 
shown to have no effect on tubule formation and membrane trafficking (244).  
In addition to membrane tubule formation and fusion events, PLA2 inhibitors 
affected organelle architecture, BFA-stimulated retrograde transport, as well 
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as retrograde trafficking of KDEL receptor chimeras (246).  In the presence of 
PLA2 inhibitors, Golgi complexes become fragmented and the assembly of 
Golgi ribbons after BFA washout is also inhibited (78, 247).  An in vitro 
reconstitution assay with PLA2 antagonists also demonstrated that intra-Golgi 
transport is dependent on PLA2 enzyme activity (248).  Conversely, activators 
of PLA2 enzymes promote Golgi membrane tubule formation (249).  In 
addition, PLA2 enzymes appear to aid in cargo transport at the TGN, as PLA2 
inhibitors block membrane tubule formation at the TGN, and decrease TGN to 
plasma membrane transport of VSV-G (250). Beyond the Golgi complex, PLA2 
antagonists decrease endocytic recycling of transferrin (Tf) and transferrin 
receptors (TfRs) as well as reduce LDL/LDL receptor, bulk fluid phase cargo, 
and EGF/EGF receptor endocytic transport (245, 251). 
 Since studies with PLA2 antagonists, several specific PLA enzymes have 
been identified to have a role in Golgi complex membrane trafficking.  A 
specific cytoplasmic, Ca2+-dependent PLA2, cPLA2α, was demonstrated to 
translocate to the Golgi complex upon increased intracellular calcium (252-
255), or with increased secretory load at the Golgi after temperature shift with 
the model cargo VSV-G (256).  Additionally, in epithelial cells cPLA2α 
translocates to the Golgi shortly after cell-to-cell contacts are formed (257, 258) 
and regulates trafficking of cell junction proteins from the Golgi complex to 
the cell-cell contacts, as shown by RNAi of cPLA2α (258).  cPLA2α was also 
shown in non-epithelial cell lines, by RNAi and antibody micro-injection 
studies, to contribute to intra-Golgi tubule connections, resulting in 
fragmentation of the Golgi stack and correlated with the reduced transport of 
VSV-G  through the cisternae (256).  However, cells from cPLA2α knockout 
mice showed no defect in VSV-G transport and only demonstrated inhibition 
 27 
of trafficking upon RNAi knockdown of one other cytoplasmic PLA2 enzyme, 
the α1 subunit of PAFAH Ib (256).   This indicates there is redundancy or 
compensation between PLA enzymes in Golgi trafficking.  As described in 
chapter 2, I have found that PAFAH Ib is a PLA2 involved in membrane 
tubule formation and is important for Golgi membrane trafficking and 
architecture (259). 
A third PLA enzyme, iPLA1γ, was shown to be involved in a different 
step of Golgi membrane trafficking, retrograde transport to the ER (260).  
iPLA1γ was localized to cis Golgi compartments and ERGIC membranes and 
was shown to have no effect on anterograde transport, but knockdown of 
iPLA1γ rather reduced BFA-stimulated retrograde membrane tubules and the 
transport of cholera toxin B from the Golgi to the ER.  However, iPLA1γ 
showed no effect on cargo that uses COPI vesicle retrograde transport 
(ERGIC-53) or on Rab6-dependent movement of cargo (shiga toxin), indicating 
iPLA1γ forms specific transport carriers for retrograde Golgi to ER trafficking 
(260). 
 
Phospholipase A Enzymes 
 There are three identified mammalian intracellular PLA1 enzymes: PA-
PLA (iPLA1α), p125 (iPLA1β), and KIAA0725p (iPLA1γ) (260).  The substrates 
and functions of these iPLA1 enzymes are just beginning to be discovered.  
iPLA1α shows preference for PA but can also act on other phospholipids; its 
role in cells is unclear (261, 262).  iPLA1β was identified to interact with Sec23, 
a COPII component, and affect ER exit sites (ERES) as well as transport to the 
Golgi complex (263, 264).  iPLA1γ was recently shown to be important for the 
formation of COPI- and Rab6-independent transport intermediates from the 
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Golgi to the ER (260). 
 The PLA2 enzyme superfamily is broken down into 15 groups based on 
protein sequence, molecular weight, localization, calcium dependency, 
function, disulfide bonds, and active site residues and further subdivided into 
five categories: secreted PLA2s (sPLA2), cytoplasmic PLA2s (cPLA2), calcium 
independent PLA2s (iPLA2), PAF acetylhydrolases (PAFAH), and lysosomal 
PLA2s (LPLA2) (265-267) (Table 1-1).  The majority of known PLA2 enzymes 
are categorized as secreted enzymes (sPLA2s, groups I, II, III, V, IX, X, XI, XII, 
XIII, and XIV), which are found in various venoms, function in the immune 
system, and are involved in inflammatory signaling.  More information on the 
thoroughly studied sPLA2 family can be found in reviews (268, 269).  Much 
less is known about the remaining groups, with detailed studies only existing 
for one or two proteins from each category of PLA2 enzymes.   
 A single lysosomal PLA2 (LPLA2, group XV) contains both a signal 
sequence and glycosylation sites indicative of secretory pathway transport 
(270).  This enzyme is optimally active at pH 4.5 and localizes with other 
lysosome-resident enzymes, supporting the role of this PLA2 in lysosome 
degradation functions (270).  LPLA2 contains active site residues of Ser, His, 
Asp (same as PAFAH enzymes) and was originally shown to esterify 
ceramide with acyl chains from phospholipid ‘donors’ (271, 272).  However, 
knockout mice of LPLA2 showed accumulated PC and PE, which were also 
shown to be preferred substrates of LPLA2 (273).  This accumulation was seen 
in macrophages and had increased foam cell formation, appearing to have 
phospholipidosis (265).   
 The cPLA2s (group IV) are generally calcium dependent, have a Ser Asp 
dyad catalytic site, and are believed to be cytosolic.  Within the cPLA2 family,  
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Table 1-1:  Phospholipase A2 enzyme families. 
 
Family Group Name(s) Localization & 
features 
Catalytic 
Residues 
Ca2+ 
dependent 
Molecular 
Mass (kDa) 
sPLA2 IA-B  secreted H/D dyad for activity 13-15 
 IIA-F  secreted H/D dyad for activity 13-17 
 III  secreted H/D dyad for activity 13-18, 55 
 V  secreted H/D dyad for activity 14 
 IX  secreted H/D dyad for activity 14 
 X  secreted H/D dyad for activity 14 
 XIA-B  secreted H/D dyad for activity 12.4-12.9 
 XII  secreted H/D dyad for activity 19 
 XIII  secreted H/D dyad for activity <10 
 XIV  secreted H/D dyad for activity 13-19 
LPLA2 XV lysosomal PLA2 lysosome lumen S/H/D triad  45 
cPLA2 IVA cPLA2α cytosol, translocates to ER and Golgi 
S/D dyad for lipid binding 85 
 IVB cPLA2β cytosol, translocates to 
membranes  
S/D dyad for lipid binding 114 
 IVC cPLA2γ prenylated, membrane-
associated 
S/D dyad none 61 
 IVD cPLA2δ cytosol, translocates to ER 
and Golgi 
S/D dyad for lipid binding 92-93 
 IVE cPLA2ε cytosol, lysosome S/D dyad for lipid binding 100 
 IVF cPLA2ζ cytosol S/D dyad for lipid binding 96 
iPLA2 VIA-1 iPLA2 cytosol S none 84-85 
 VIA-2 iPLA2β cytosol, membrane-
associated 
S none 88-90 
 VIB iPLA2γ prenylated, membrane-
associated 
S none 88-91 
 VIC iPLA2δ, NTE transmembrane protein S none 146 
 VID iPLA2ε, 
PNPLA3, 
adiponutrin 
lipid droplets S none 53 
 VIE iPLA2ζ, 
PNPLA2, ATGL 
lipid droplets S none 57 
 VIF iPLA2η, 
PNPLA4 
cytosol S none 28 
PAFAH VIIA plasma PAFAH, 
LpPLA2 
secreted S/H/D triad none 45 
 VIIB PAFAH II myristoylated, translocates 
to membranes 
S/H/D triad none 40 
 VIIIA PAFAH Ib α1 cytosol, Golgi S/H/D triad none 29 
 VIIIB PAFAH Ib α2 cytosol, Golgi S/H/D triad none 30 
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enzymes have slightly different sn-2 fatty acid specificity.  cPLA2α is specific 
for arachidonic acid, a well-known molecule in inflammatory signaling 
pathways, whereas other cPLA2 members preferentially act on linoleic acid, 
but can also cleave oleic acid and arachidonic acid (274, 275).  All cPLA2s, 
except cPLA2γ, are Ca2+-dependent, requiring Ca2+ for the C2 domain of these 
enzymes to bind lipids (276-278).  cPLA2γ is instead prenylated and 
constitutively associates with membranes (277).  The best characterized cPLA2 
is cPLA2α, which is the only PLA2 with preference for phospholipids having 
arachidonic acid in the sn-2 position (267, 275).  This enzyme also behaves as a 
lysophospholipase and a transacylase enzyme (279, 280).  cPLA2α translocates 
to ER and Golgi membranes upon: an increase in cellular calcium, an acute 
increase in Golgi secretory load, an increase in PIP2 and PIP3 levels, upon 
cPLA2α binding of ceramide-1-phosphate, and upon MAP kinase 
phosphorylation of cPLA2α (256, 281-285).  cPLA2α knockout mice primarily 
show changes in inflammatory signaling, likely through decreased production 
of arachidonic acid for generation of inflammatory eicosanoids (266).  cPLA2α 
knockout mice and/or human patients with defects in cPLA2α also have 
increased intestinal ulcers, decreased damage from acute lung or brain injury, 
decreased anaphylaxis, spermatozoa with impaired mobility, and lower birth 
rate (286-290). 
 iPLA2s (group VI) are generally Ca2+-independent and vary in their 
substrate specificity as well as their intracellular distribution.  These enzymes 
share a GXSXG lipase consensus motif, with a catalytic Ser residue and do not 
appear to have much if any selectivity for sn-2 fatty acids (291-293).  The 
enzymes in this group primarily act as PLA2 enzymes, but iPLA2 and iPLA2β 
appear to also have lysophospholipase and transacylase activity (294).  Several 
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iPLA2s, including iPLA2ε (PNPLA3), iPLA2ζ (PNPLA2), and iPLA2η 
(PNPLA4) were found to additionally have roles in energy homeostasis and 
triacylglycerol metabolism, for which they are being extensively studied (293, 
295).  The iPLA2s involved in metabolism are also known as patatin-like 
phospholipase domain containing proteins (PNPLAs), which are reviewed in 
(295).  iPLA2s have many intracellular distributions, from cytoplasmic iPLA2 
and iPLA2β, to lipid droplet associated iPLA2ζ, and membrane-bound iPLA2γ 
(265, 295).  The integral membrane iPLA2δ has been shown to be involved in 
neuropathies such as Wallerian degeneration, also known as neuropathy 
target esterase (NTE) (266, 296).  NTE was identified as the Drosophila swiss 
cheese mutant protein, which shows glial cell hyperwrapping of axons and 
eventual axonal degeneration (297).  iPLA2δ cleaves acyl chains at the sn-2 
position of PC, then subsequently cleaves the sn-1 position acyl chains (266, 
298). 
  The family of PLA2 enzymes known as PAFAHs (group VII and VIII) 
contain intracellular and secreted enzymes, both of which share a common 
Ca2+-independent activity through a Ser, His, Asp catalytic triad and act on 
platelet activating factor (PAF) as a substrate (299-302).  PAF is a 
phosphatidylcholine ether lipid, with an ether linked acyl chain in the sn-1 
position (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) (303).  Similar to 
ether linked plasmologen lipids (which have a vinyl-ether sn-1 linkage), PAF 
is most prevalent in endothelial cells and cells of the immune system but can 
also be found in extremely small quantities in other cell types (303-305).  PAF 
is both intracellular and extracellular; PAF levels have been measured in 
blood, saliva, amniotic fluid during labor, and urine (303).  PAF has been 
implicated in many signaling functions: inducing acute inflammatory 
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reactions, anaphylaxis responses, platelet aggregation, roles in neuronal and 
testicular function, as well as chemotaxis and granule secretion of neutrophils 
and monocytes (299, 303, 306-310).  Several of the signaling roles for PAF can 
be attributed to its binding and activation of transmembrane PAF receptors 
(PAFR), which are G protein coupled receptors (GPCRs) found in cells of the 
innate immune system and central nervous system that bind to extracellular 
PAF (299, 311).  
 Group VII PAFAH enzymes can cleave the sn-1 or sn-2 position acyl 
chain of a broad array of substrates, which includes PAF, TAG and DAG with 
varying fatty acid chain lengths, phospholipids with short sn-2 position fatty 
acids as well as on oxidized lipids (265, 312).  Group VIIA consists of a single 
secreted PLA2 also known as lipoprotein-associated lipase (LpPLA2) or plasma 
PAFAH (266, 313, 314).  This PAFAH has been studied extensively for its role 
in lipoprotein association, possible role in cardiovascular disease, and as a 
marker of coronary heart disease (315, 316).  The enzyme of group VIIB shares 
similar specificity to group VIIA but is intracellular with myristoylation at its 
N-terminus; it can translocate from the cytosol to membranes during oxidative 
stress (265, 317).  Group VIII PLA2 PAFAH Ib is discussed in detail in the 
following section.   
  
Platelet Activating Factor Acetylhydrolase Ib 
This phospholipase complex of group VIII PLA2 enzymes consists of 
two catalytic subunits that share a GXSXV lipase motif and a Ser, His, Asp 
catalytic triad (318, 319).  PAFAH Ib forms homo- or heterodimers of α1 
(Pafah1b3) and/or α2 (Pafah1b2).  Dimerization is needed for catalytic activity 
(320), as the catalytic triad lies within a cleft between the two subunits  
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(Figure 1-3) (321).  Mutations of the catalytic Ser for either subunit yield a 
catalytically inactive enzyme (322).  PAFAH Ib catalytic subunits were 
originally identified for their ability to cleave the PAF sn-2 position acetyl 
group, or acyl chains less than six carbons in length, to generate a lyso-PAF 
(319, 322).  However, in vitro studies that examined cleavage of 1-O-alkyl-2-
acetyl-glycerophospholipids (AAG phospholipids) with different head groups 
suggest that α1 and α2 have other possible phospholipid substrates 
depending on the dimer composition.  Dimers of α1/α1 or α1/α2 show 
activity for cleaving PAF, and AAG PA (phosphatidic acid head group), but 
had little activity for AAG PE (ethanolamine head group).  Homodimers of 
α2/α2 had considerably higher PAF acetylhydrolase activity, AAG PE 
activity, and moderate AAG PA activity (323).  
Human and bovine PAFAH Ib α1 and α2 are 63% identical at the amino 
acid level and within subunits have 95-100% conservation of amino acid 
sequence among mammalian species.  Studies in rats and mice indicate both 
α1 and α2 mRNAs are expressed in fetal development, but α1 mRNA 
expression progressively declines until undetectable in adulthood (324, 325).  
PAFAH Ib α1 and α2 protein levels were ubiquitous in mouse tissues (326), 
however, α1 showed higher expression during development, α1 and α2 were 
highest in brain and testis, and α2 also showed higher expression in lung 
tissue (326).  Expression levels of α1 and α2 subunits in bovine tissues were 
ubiquitous, and did not demonstrate the decrease in α1 mRNA expression 
observed in adult mice.  The highest amounts of bovine α1 mRNA expression 
were found in fetal brain, but significant levels were found in adult bovine 
kidney, human kidney, thymus and colon (327, 328).  Conservation among 
non-mammalian species has only been confirmed in Drosophila melanogaster,  
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Figure 1-3:  Structure of PAFAH Ib.  (A) Space filling structure of an α1/α2 
(blue/yellow) heterodimer with the catalytic pocket showing the Ser, His, Asp 
catalytic triad in red.  Based on (331).  (B) Structure of the PAFAH Ib complex 
with a dimer of LIS1 in turquoise bound to an α2/α2 homodimer 
(yellow/orange).  The catalytic pocket is facing downward in this structure.  
Based on (341).  (C) Structure of an α2/α2 homodimer, with catalytic serines 
(Ser 48) highlighted in red and LIS1-binding important E39 residues 
highlighted in white.  The catalytic pocket is facing downward. 
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whose homologues lack two of the three catalytic residues, hence do not have 
catalytic activity (329).  The exact function for the PAFAH Ib catalytic subunits 
has been unclear, particularly because knockout mice of α1 and α2 subunits 
had limited phenotypes.  PAFAH Ib α1-/- mice were grossly normal, α2-/- 
mice had reduced testes weight and inconsistent germ cell defects.   Double 
mutants of α1-/-/α2-/- had increased apoptosis in cells of seminiferous tubules 
leading to more severe spermatogenic phenotypes (326, 330). 
PAFAH Ib α subunits can be isolated in a protein complex, as it was 
originally purified as a trimer of two α subunits and a β subunit.  The third β 
subunit was predicted to be regulatory (322).  Later studies determined that 
α1 and α2 form a tetrameric structure with a homo or heterodimer of α1 
and/or α2 and a dimer of LIS1 subunits (Figure 1-3) (331).  The β subunit was 
later identified to have 99% amino acid identity with the protein LIS1 (gene 
Pafah1b1), a protein involved in dynein regulation (discussed more below).  
LIS1 has been investigated extensively for its association with a severe neural 
development disease known as lissencephaly, which is Greek for smooth 
brain.  Mutations in Pafah1b1 subdivide into two types of congenital, 
autosomal dominant lissencephaly: Miller-Dieker syndrome and type 1 
isolated lissencephaly (332, 333).  Loss of both copies of LIS1 is lethal (334).  
While neurons appear to be extremely sensitive to levels of LIS1, it has 
functions in all cell types.  LIS1 is conserved within eukaryotes, and amino 
acid sequences of LIS1 are >99% identical within mammalian species.  
Expression of LIS1 is ubiquitous (326, 333) but found at higher levels during 
development, and in brain, testis, and lung of mice (326). 
The relevance of catalytic α1 and α2 subunit interactions with LIS1 is 
still unclear.  The catalytic subunits have not been associated with 
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lissencephaly and have been found to function independently of LIS1 binding 
(318).  Binding to LIS1 appears to increases the catalytic activity four-fold 
specifically for α2/α2 dimers but not other dimer combinations in vitro (323).  
Interactions between LIS1 and α1 and α2 have only been found in mammals; 
these proteins do not interact in Drosophila (329) and α1 and α2 homologues 
have not been identified in other species where LIS1 homologues exist.   
Heterozygous loss of LIS1 combined with loss of α2 (α2-/- Lis1-/+) in mice 
showed fewer spermatogenic defects than α2 -/- (330).  The reason for this 
reduced phenotype severity with α2 loss is not understood.   
Differences between α1 and α2, beyond catalytic preference and 
increased activity with LIS1, were found in studies of PAFAH Ib subunits 
with the reelin receptor pathway.  Reeler mice, which have loss of functional 
reelin, a ligand for both VLDLR and ApoER2 receptors, show neuronal 
phenotypes of abnormal cortical neuritogenesis.  Ndel-/-/Lis1+/- mice 
phenocopy reelin disruption (Reln-/-) in reeler mice, with cortical layer 
disruption, cerebellar hypoplasia and ataxia (335).  Both LIS1, α1, and α2 have 
been shown to interact with components of the reelin receptor pathway, and 
mouse knockouts indicate that α1 versus α2 have different effects on LIS1 
genetic interactions with the reelin receptor pathway.  Surprisingly, LIS1-/+ in 
combination with loss of reelin pathway components showed exacerbated 
phenotypes with loss of α1 (α1-/-) and suppressed phenotypes with loss of α2 
(α2-/-) (336).  This adds another layer of complexity to the functional roles of 
α1 and α2 and how α subunits affect LIS1 functions. 
PAFAH Ib α subunits have been shown to affect LIS1 function.  α1 and 
α2 compete for binding to LIS1 with Ndel1, another dynein regulatory protein 
(331).  In this study, α2 appeared to be a better competitor, indicating that α2 
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may bind LIS1 with higher affinity than α1 (331).  The overexpression of α1, 
but more dramatically α2, was shown to reduce LIS1 binding to dynein, 
resulting in delayed mitosis due to spindle formation defects as well as 
disorganized microtubules during interphase (337).  This reduction in LIS1-
dynein interaction was no longer seen when overexpressing α1 E38D or α2 
E39D mutants that abolish LIS1 binding (337).  Other studies have confirmed 
this delay in mitosis and further found that overexpression of α1 or α2 
resulted in Golgi fragmentation and a peripheral distribution of endosomes as 
seen by labeling with wheatgerm agglutinin (338).  Overexpression of α 
subunits also impaired migration of cortical neurons (338).  Similar to the 
studies by Yamaguchi et al (337), these effects were found to be dependent on 
titration of LIS1 from Ndel1 and dynein by overexpression of α1 or α2 (338).  
Both of these reports indicate that there is a balance between LIS1 binding to 
dynein and LIS1 binding to the catalytic subunits of PAFAH Ib.  This 
additionally suggests that α1 and α2 can regulate LIS1-activation of dynein.   
 
LIS1 and Dynein Function in Membrane Trafficking 
While it is debated exactly how LIS1 contributes to dynein function, it 
is generally accepted that LIS1 aids in activating dynein minus-end directed 
microtubule transport (339).  Dynein motors form complexes with a variety of 
regulatory proteins including LIS1, the dynactin complex, CLIP-170, Bicaudal 
D, Spindly, Rod/ZW10/Zwilch, Ndel1, and NDE1 (340).  Current research is 
examining which dynein functions are regulated by these proteins. 
There are at least three members of the cytoplasmic dynein family (341, 
342); dynein1 is the most abundant member.  Dynein1 is important for the 
positioning of microtubules in cells, spindle orientation during mitosis, 
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organelle positioning, and transport of cargo in several intracellular trafficking 
events (dynein functions are reviewed in (68, 340, 343).  Dynein1 binds to the 
activator protein complex dynactin, which is a multi-subunit complex 
consisting of Arp1 (actin related protein), Arp11, p150Glued, dynamitin (p50), 
CapZ α or β, actin, p62, p25, p24, and p27 (344).  The dynactin complex is 
believed to link dynein to the cargo it carriers (344-346) and may help facilitate 
long-range movement (347, 348).   
The steady state distribution of the ER, Golgi, endosomes, and 
lysosomes has been shown to be dependent on microtubule motor protein 
function.  Bidirectional movement of endosomes occurs along microtubule 
tracks involving both kinesin motors to move cargo to the cell periphery 
(towards microtubule + ends) and dynein, which generally moves organelles 
and cargo toward the (microtubule - ends) microtubule organizing center 
(MTOC, aka centrosome) at the cell center.  Dynein and dynactin have been 
shown to be critical for the position of endosomes, lysosomes, and the Golgi 
complex (65, 66).  Inhibition of dynein activity by dynamitin overexpression, 
which interferes with the dynactin complex formation, shows Golgi 
fragmentation and relocation of early endosomes, recycling endosomes (ERC), 
late endosomes, and lysosomes to the cell periphery (66, 349).    
Dynein and kinesin split responsibilities in the movement of transport 
intermediates between organelles (Figure 1-1).  Transport from the Golgi 
complex to the ER is dependent on kinesin, while ER to Golgi trafficking is 
dynein/dynactin dependent (179).  Studies demonstrate dynein/dynactin 
transport of cargo from early to late endosomes, but dynein/dynactin does 
not affect Tf recycling out of the cell (349).  These results were confirmed with 
antibody microinjection, dynamitin overexpression, and dynein knockout 
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mouse studies (65, 66, 349).  Dynein is important for early endosome to ERC 
transport (350).  Kinesin motors are believed to mediate the movement of 
cargo from endosomes to the plasma membrane.  For more details on kinesins, 
see (351). 
LIS1 contributes to many roles of the dynein/dynactin complex (352-
355) and is consistently shown localized to plus ends of microtubules, to the 
centrosome, and to kinetochores during cell division (352, 356).  LIS1 
contributes to dynein-dependent connections of the nucleus to the centrosome 
and the microtubule network (353, 357), which is critical for cell migration.  
Decreased levels of functional LIS1 lead to a loss of these connections, which 
may contribute to the defects in neuronal migration observed in lissencephaly 
(339). 
Additionally, LIS1 expression levels impact the mitotic spindle, 
centrosome position, radial microtubule arrays and both the morphology and 
localization of secretory and endocytic organelles, including the Golgi 
complex (352, 358, 359).  Increased or decreased levels of LIS1 generate spindle 
abnormalities that result in defective chromosomal alignment (352).  High 
expression levels of LIS1 shift the distribution of dynein and p150Glued 
(dynactin component) to the cell center, indicating that LIS1 increases the 
minus-end directed transport of dynein (358).  LIS1 levels affect the 
distribution of the Golgi complex, as Lis1+/- fibroblasts showed dispersed 
Golgi, and the addition of LIS1 to these cells returned the Golgi to a more 
centrally clustered organelle (358).  Conversely, the overexpression of LIS1 in 
Cos7 cells resulted in a more compact Golgi (358).  LIS1 has also been shown 
to affect the positioning of endosomes and lysosomes, irrespective of the 
microtubule organization, indicating that LIS1 must regulate dynein-
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dependent transport of these organelles (360).  This is not an exhaustive 
review of LIS1 and the multitude of LIS1 studies is reviewed in (339, 361). 
 
Research Goals  
 Previous work demonstrated that PLA2 activity is important for 
membrane tubule formation as well as secretory and endocytic trafficking 
steps (78, 79, 244, 245, 250, 251) (Figure 1-1).  The specific PLA2 enzyme(s) 
involved in these processes was unknown.  The co-fractionation of PAFAH Ib 
with Golgi membrane tubule-stimulating activity from cytosol led to the 
hypothesis that PAFAH Ib is involved in Golgi membrane tubule formation 
and membrane trafficking events.  I set out to examine the potential role of 
PAFAH Ib subunits in Golgi membrane tubule formation, Golgi complex 
structure, and trafficking (Chapter 2).  As α1 and α2 subunits form both 
homo- and hetero-dimers, which have been shown to genetically and 
biochemically differ (323, 331, 336), I also investigated whether α1 and α2 have 
overlapping or distinct roles at the Golgi complex (Chapter 3).  The role for 
PAFAH Ib in endocytic trafficking was also investigated (Chapter 4).  
Additionally, to determine how PLA2 activity in Golgi membrane tubule 
formation is regulated, I investigated the role of heterotrimeric G protein Gβγ 
subunits, as Gβγ subunits have been implicated in Golgi complex structure, 
tubule formation, and trafficking (97, 362) (Chapter 5). 
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CHAPTER 2 
 
The Phospholipase Complex PAFAH Ib Regulates the Integrity and 
Trafficking of the Golgi Complex1 
 
Abstract 
We report that Platelet Activating Factor Acetylhydrolase (PAFAH) Ib, 
comprised of two phospholipase A2 (PLA2) subunits, α1 and α2, and a third 
subunit, the dynein regulator LIS1, mediates the structure and function of the 
Golgi complex.  Both α1 and α2 partially localize on Golgi membranes, and 
purified catalytically active, but not inactive, α1 and α2 induce Golgi 
membrane tubule formation in a reconstitution system.  Overexpression of 
wild type or mutant α1 or α2 revealed that both PLA2 activity and LIS1 are 
important for maintaining Golgi structure.  Knockdown of PAFAH Ib 
subunits fragment the Golgi complex, inhibit tubule-mediated reassembly of 
intact Golgi ribbons, and slow secretion of cargo.  Our results demonstrate a 
cooperative interplay between the PLA2 activity of α1 and α2 with LIS1 to 
facilitate the functional organization of the Golgi complex, thereby suggesting 
a model that links phospholipid remodeling and membrane tubulation to 
dynein-dependent transport. 
 
Introduction 
An unresolved feature of the Golgi complex is the role of membrane 
tubules in trafficking and maintenance of Golgi architecture (96, 97, 363). 
Within the Golgi, membrane tubules are implicated in cis to trans cargo 
                                                 
1 ©Bechler et al., 2010.  Originally published in J Cell Biol. doi: 10.1083/jcb.200908105 
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cisternal transport (46, 47), retrograde trafficking to the endoplasmic reticulum 
(ER) (14, 176), transport from the trans Golgi network (TGN) to the cell surface 
and endosomes (96, 97, 186, 189), and in the assembly and maintenance of 
intact Golgi ribbons (78, 244).   
Pharmacological studies have shown cytoplasmic phospholipase A2 
(PLA2) enzymes regulate the formation of Golgi membrane tubules that 
contribute to retrograde trafficking, and the assembly and maintenance of an 
intact Golgi ribbon in mammalian cells (78, 242, 244, 246, 249, 364).  Here we 
identify Platelet Activating Factor Acetylhydrolase Ib (PAFAH Ib) as a 
cytoplasmic PLA2 complex that regulates membrane tubule formation, 
organization and function of the Golgi complex.  PAFAH Ib was originally 
purified based on its ability to hydrolyze the sn-2 position acetyl group of the 
signal transducing, phosphatidylcholine derivative, Platelet Activating Factor 
(PAF) (318, 322, 365).   PAFAH Ib consists of homo- or hetero-dimers of two 
closely related catalytic subunits, α1 (Pafah1b3) and α2 (Pafah1b2), and a non-
catalytic dimer of β subunits (Pafah1b1) (302, 321, 331).  The β subunit is better 
known as LIS1, the causative agent of the fatal brain disorder Miller-Dieker 
lissencephaly (366).  LIS1 is a highly conserved protein involved in dynein-
mediated processes including nuclear and neuronal migration, centrosomal 
function, and mitotic spindle orientation (339, 367).  Although PAFAH Ib has 
been implicated in a variety of processes, including the regulation of PAF and 
LIS1 functions, its exact biological function is unclear, as α1-/-/α2-/- double 
knockout mice, while exhibiting defects in spermatogenesis, are otherwise 
normal (326, 330).   
Using multiple in vitro and in vivo approaches, we find that all three 
subunits of PAFAH Ib contribute to the structure of the mammalian Golgi 
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complex, and the catalytic subunits independently contribute to secretion.  
Our results suggest a model whereby the PLA2 activity of α1 and α2 remodel 
membrane phospholipids to form Golgi tubules, which are linked via LIS1 to 
dynein-mediated, microtubule transport. 
 
Materials and Methods 
Reagents 
Sprague-Dawley male rats were obtained from Charles River Breeding 
Laboratories, Inc.  BFA and cycloheximide were from Biomol Research 
Laboratories, Inc.  Antibodies were as follows: guinea pig anti-α1 antibody (A. 
Doody); rabbit anti-bovine CI-M6PR (by us (368)); rabbit anti-dynamin 
(MC63) (M. McNiven, Mayo Clinic, Rochester, MN); rabbit anti-human 
GPP130 (A. Linstedt, Carnegie Mellon Univ., Pittsburgh, PA); rabbit anti-
ManII (K. Moremen, Univ. of Georgia, Athens, GA); chicken anti-α2 (Abcam, 
Inc.); mouse anti-LIS1 (Sigma Chemical Co.); mouse anti-HA (Covance); 
mouse anti-β-COP (BioMakor), mouse anti-α tubulin (Sigma Chemical Co.), 
rabbit anti-γ-adaptin (Santa Cruz), rabbit anti-Sec31A (W. Balch, Scripps 
Research Institute, La Jolla, CA) fluorescent secondary antibodies (Jackson 
Immuno-Research Laboratories and Invitrogen); HRP-conjugated goat anti-
chicken (Aves Laboratories), anti-guinea pig (Pocono Rabbit Farm and 
Laboratory), anti-rabbit (GE Healthcare), and anti-mouse (Gibco). 
 
Preparation of Plasmids  
The protein purification vectors pGEX6P1-α1-S47A and pGEX6P1-α2-
S48A were generated by Anne Doody and Lin Lin ((259); Anne Doody 
dissertation).  The protein purification vectors pGEX4T1-α1 and pGEX4T1-α2 
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were gifts of Dr. Z. Derewenda (University of Virginia, Charlottesville, VA). 
pGEX4T1-α1-E38D and pGEX4T1-α2-E39D were generated by site-directed 
mutagenesis with the Quickchange II Site-directed mutagenesis kit 
(Stratagene) using the following primers (mutations are bold): 
α1: 5’-GAAGACGACTTCGGGATCCTTATCTTTGCTGTCG-3’ 
      5’-CGACAGCAAAGATAAGGATCCCGAAGTCGTCTTC-3’ 
α2: 5’-GGACATCCGGGTCTTTGTCTTTGCAGTCCAGG -3’ 
      5’-CCTGGACTGCAAAGACAAAGACCCGGATGTCC-3’ 
Although our polyclonal antibodies were useful for Western blots, we 
were unsuccessful in localizing endogenous α1 and α2 with many different 
polyclonal antibodies (made in rabbit, guinea pig, chicken, rat).  Therefore, 
Anne Doody and Lin Lin generated mammalian expression constructs 
containing internally HA-tagged α1 and α2 (pEN1-α1-HA, pEN1-α2-HA, and 
pEN1-α2-S48A-HA) by insertion on surface loops (α1 G165 and α2 P130) 
based on (321), that would not interfere with dimer or LIS1 interactions 
mammalian expression vectors. 
Mammalian expression plasmid pEN1-α1-S47A-HA was made by site-
directed mutagenesis using Quickchange II (Stratagene) with the following 
primers: 5’-TCGTCTTCATCGGTGACGCCTTGGTCCAGCTGATGC-3’ and 
5’-GCATCAGCTGGACCAAGGCGTCACCGAATGAAGACGA-3’.  RNAi 
resistant pEN1-α1-HA, pEN1-α1-S47A-HA, pEN1-α2-HA, and pEN1-α2-
S48A-HA were generated by making two silent mutations in the dsRNA 
target sequence, using primers:   
α1: 5’-GTGTTCCAGCTCGCCGTTCTCCAGACGCCAC-3’ 
       5’-GTGGCGTCTGGAGAACGGCGAGCTGGAACAC-3’ 
α2: 5’-GGTTTAATATTCTCCAGCTCGCCATTCTTTAGTCTCC-3’ 
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      5’-GGAGACTAAAGAATGGCGAGCTGGAGAATATTAAACC-3’ 
LIS1 binding mutants α1 E38D or α2 E39D (337) were generated, with the help 
of Ina Chen, by site-directed mutagenesis of RNAi resistant pEN1-α1-HA, 
pEN1-α2-HA, pEN1-α1-S47A-HA, and pEN1-α2-S48A-HA with the following 
primers:  
α1: 5’-GAAGACGACTTCGGGATCCTTATCTTTGCTGTCG-3’ 
      5’-CGACAGCAAAGATAAGGATCCCGAAGTCGTCTTC-3’ 
α2: 5’-GGACATCCGGGTCTTTGTCTTTGCAGTCCAGG -3’ 
      5’-CCTGGACTGCAAAGACAAAGACCCGGATGTCC-3’ 
 pCMV-HA-LIS1 was a gift from Dr. R. Vallee (Columbia University, 
New York, NY).  The sequence of this LIS1 contained a point mutation A166T 
that was reverted back to alanine using site-directed mutagenesis using 
primers: 5’-GCGGCAAGCTTCTGGCTTCCTGTTCTGC-3’ and  
5’-GCAGAACAGGAAGCCAGAAGCTTGCCGC-3’.  RNAi-resistant pCMV-
HA-LIS1 was created by site-directed mutagenesis to generate two silent 
mutations in the dsRNA target sequence using primers:  
5’- GGATTACAAGAACAAGCGCTGTATGAAGACCCTCAATGCGC -3’ and 
5’-GCGCATTGAGGGTCTTCATACAGCGCTTGTTCTTGTAATCC -3’. 
 
Protein Purification 
Vectors were prepared as described above and transformed into the 
competent BL21 E. coli strain. Proteins were purified and cleaved from GST 
using the GST-3C-Pro system or thrombin (Sigma Chemical Co.) as described 
by GE Healthcare (also found in detail A. Doody dissertation).  
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In Vitro Golgi Tubulation Assay and Mass Spec Protein Identification 
Reconstitution of Golgi membrane tubule formation and fractionation of 
BBC was as described (369).  Briefly, BBC was fractionated by a series of 
centrifugations to remove particulate material and several ammonium sulfate 
precipitations.  A soluble fraction was subjected to a series of chromatographic 
separations including phenyl-sepharose, DE52 ion exchange, Affi-Gel blue, 
and finally gel filtration (GF) on Sephadex G100 that yielded a GF highly 
enriched in tubulation activity.  GF fraction proteins were separated and 
identifiec using MALDI TOF-TOF as described in (259) (A. Doody, K. Lee). 
BBC was combined with antibodies or purified proteins as described in the 
Results. 
 
PAFAH Activity Assay 
The PAFAH assay was used to confirm activity of PAFAH Ib α1 and α2 
purified proteins, using substrate 2-Thio PAF, was performed as described by 
the supplier (Cayman Chemical). 
 
Cell Culture, Transfection and RNAi  
BTRD bovine testicular and HeLa cells were cultured in MEM 
(Mediatech, Inc.) with 10% bovine growth serum (BGS) or NuSerum in a 37°C, 
95% humidity, and 5% CO2 incubator.  Lipofectamine 2000 (Invitrogen) was 
used with modifications: DNA and reagent were reduced to a quarter.  
Experimentation was 24-48 h later.  Double stranded RNA targeting bovine α1 
mRNA and bovine α2 mRNA were from Dharmacon: 
AGAAUGGAGAGCUGGAACAUU and GGAGAACUGGAGAAUAUUAUU, 
for α1 and α2 respectively.  LIS1 dsRNA was from Dharmacon, sequence from 
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Tsai et al., 2005: GAACAAGCGAUGCAUGAAG.  Control RNA was 
siGenome non-targeting siRNA #1 and #2 (Dharmacon).  RNA was 
transfected on two consecutive days with Lipofectamine RNAiMax 
(Invitrogen) and 30 nM RNA.  Experiments were 48 h or 72 h after the initial 
RNA transfection.   
 
Cell Fractionation 
 Linear sucrose gradients were prepared by repeated freeze-thaw cycles 
of a 4-step sucrose gradient, containing 1.5 mL 48%, 4 mL 39%, 4 mL 35%, and 
4 mL 29% sucrose with 10 mM Tris, pH 7.4.  BTRD cells were grown to 
confluency in six 24 x 24 cm dishes, washed with PBS (pH 7.4), harvested by 
scraping, and kept at 4oC or on ice.  Cells were pelleted by low speed 
centrifugation and washed 3 times in homogenization buffer (0.25 M sucrose, 
1 mM EDTA, 10 mM Tris, pH 7.4).  Cells were homogenized in a Balch-
Rothman apparatus, followed by a low speed centrifugation to obtain post-
nuclear supernatant.  The post-nuclear supernatant (~5 mL) was loaded on top 
of a linear 20-49% sucrose (10 mM Tris, pH 7.4) gradient and centrifuged in a 
SW28.1 rotor in a Beckman Coulter Optima LE-80K ultracentrifuge 
(Beckman Instruments) at 25,000 rpm for 2 h at 4oC with no brake. One-
milliliter fractions were collected from the cell fractionation gradient, prepared 
for SDS-PAGE and subsequent Western blotting.  Fractions from a second 
parallel gradient were collected and used to measure sucrose concentration 
with an Abbe refractometer (Bausch & Lomb).  
 
Fluorescence Microscopy  
For direct fluorescence of GFP or YFP tagged proteins, cells were fixed in 
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3.7% formaldehyde in PBS for a minimum of 10 min at room temperature, 
washed in PBS three times for 5 min each, mounted with Vectashield (Vector 
Laboratories) mounting media, and stored at -20oC until imaged.   For 
immunofluorescence, cells were fixed in 3.7% formaldehyde in PBS for a 
minimum of 10 min at room temperature, washed in PBS for 5 min three times 
and permeabilized with 0.1% Triton X-100 in PBS for 10 min.  Cells were then 
incubated for one hr at room temperature or overnight at 4oC with primary 
antibodies diluted in PBS, followed by three washes in PBS and secondary 
antibody incubation for 1 h at room temperature.  Coverslips were mounted 
with Vectashield (Vector Laboratories) mounting media, stored at -20oC until 
imaged.  Primary antibodies were diluted as follows: anti-HA, anti-Sec31A 
anti-ManII, anti-β-COP, anti-α tubulin, and anti-γ-adaptin 1:100; anti-bovine 
CI-M6PR 1:200; and anti-GPP130 1:1000. Secondary antibodies conjugated to 
Alexa 488, DyLight 488, fluorescein isothiocyanate, tetramethylrhodamine 
isothiocyanate, or Cy5 were used, diluted in PBS 1:500 for Alexa488 and 1:100 
for all other secondary antibodies.  Wide-field epifluorescence was with Zeiss 
Axioscope II, Zeiss 40x or 100x Plan-Apochromat NA1.4 oil objective lenses, a 
Hamamatsu Orca II digital camera, and Openlab software (Improvision).  
Spinning disk confocal images were taken with a Nikon Eclipse TE2000-U, 
Nikon Plan-Apo 60xA/N1.4 or Nikon Plan-Apo100x/N1.4 oil objectives, with 
Perkin-Elmer Ultraview LCI, a Hamamatsu 1394 ORCA-ER camera, and 
Perkin-Elmer Ultraview software.  A Leica DMI6000B microscope equipped 
with a Leica oil 63x/NA1.4 objective, 3i Marianas spinning disk system, 
Photometrics HQII CCD camera, and 3i Slidebook 5.0 software was also used 
(Intelligent Imaging Innovations).   
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VSVG-YFP and ssHRP-Flag  
ts045VSVG-YFP pixel intensities of the juxtanuclear Golgi region and 
total cell were measured per cell from confocal images using ImageJ (NIH), 
with appropriate background fluorescence subtraction (per area).  Kinetic 
equations for ts045VSVG-YFP transport were fit by least squares non-linear 
regression using Origin 3.5 software, based on first order kinetic equations 
(181).  For ssHRP-Flag measurements, media and lysate HRP activity was 
quantified by absorbance, using 3, 3’, 5, 5’-tetramethyl-benzidine reagent 
(Sigma), and normalized to total HRP expression.   
 
Electron Microscopy 
Cells were fixed in the dish using 1.5% glutaraldehyde fixative (with 
5% sucrose and 0.1 M Na cacodylate) for 1 h, followed by three 15 min 4oC 0.1 
M Na cacodylate washes, and post-fix in osmium tetroxide (1% OsO4, 1% 
KFeCN, 0.1 M Na cacodylate) for 1 h at 4oC.  Cells were washed three times 
for 15 min in 4oC 0.1 M Na cacodylate then stained with 0.25% uranyl acetate 
for 30 min, followed by an additional three Na cacodylate washes.  Cells were 
dehydrated using 70%, 95%, and 100% ethanol washes then removed from the 
dish with propylene oxide.  Cells were pelleted in a micro-centrifuge and 
infiltrated with 1:1 propylene oxide and Spurs for 30 min.  The supernatant 
was removed and replaced with 100% Spurs overnight.  The Spurs was 
replaced twice more and polymerized at 60°C for 24 h. The polymerized block 
was sectioned and stained with lead citrate and uranyl acetate. For electron 
microscopy images, a FEI Morgagni 268 transmission EM was used. 
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Image Analysis and Statistics 
The Golgi disruption indices were by categorizing Golgi as diffuse, 
fragmented, or intact.  For most experiments, > 300 cells were counted for each 
condition, and each was repeated independently > three times.  The statistical 
significance between control and knockdown cells was with a two-tailed, 
unequal variance T-test.   The significance of overexpression phenotypes was 
by Behrens-Welch testing.  Images and z-projections were cropped, brightness 
adjusted, or contrast adjusted using ImageJ, Photoshop CS3, or using 3i 
Slidebook 5.0 software.  Three-dimensional reconstruction was done using 
Volocity software (Improvision).  Line intensity plots were done using 3i 
Slidebook 5.0 software (Intelligent Imaging Innovations).  
 
Results and Discussion 
PAFAH Ib α1 and α2 are Cytoplasmic Membrane Tubulation Factors 
Previous studies showed that a preparation of bovine brain cytosol (BBC) 
contains PLA2 activity that stimulates Golgi membrane tubule formation in a 
cell-free system (78).  In collaboration with other members of the Brown lab, we 
identified a specific PLA2 responsible for this tubulation activity.  Biochemical 
fractionation of BBC yielded a final gel filtration (GF) fraction highly enriched 
(~5,400 fold) in tubulation activity, with native molecular weight of 150-170 kD 
(369), and containing co-fractionating proteins of ~80, 66, 45, 40, 30 and 18 kD 
(Figure 2-1).  MALDI TOF-TOF and Western blotting identified the 45 kD band 
as LIS1 and the 29-30 kD bands as α1 and α2 catalytic subunits of PAFAH Ib 
(Figure 2-1).  Other proteins identified in the GF fraction were Hsc70, PLA2 
activating protein (PLAA), and fructose bis-phosphate aldolase.  A variety of 
experiments showed that aldolase is a contaminant; the role of Hsc70 and 
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PLAA in tubule formation, if any, remains to be determined.    
  To determine if PAFAH Ib is directly involved in membrane tubule 
formation, purified α1 or α2 were added to isolated Golgi complexes in vitro.  
Alpha subunits alone were unable to stimulate membrane tubules in the 
absence of BBC (Figure 2-2; A. Doody dissertation).  However, when α1 or α2  
were mixed with sub-threshold amounts of BBC, catalytically active α1 and 
α2, but not inactive enzymes with single amino acid changes in active site 
serines (α1 S47A; α2 S48A) (318), significantly induced Golgi membrane 
tubule formation (Figure 2-1 D, E). This cytosol requirement was not due to 
LIS1, because α1 or α2 mutants that do not bind to LIS1 (α1 E38D and α2 
E39D) (337) stimulated membrane tubules (Figure 2-2).  Consistent with these 
results, antibodies against α1 and α2 (but not pre-immune antisera) inhibited 
BBC-dependent in vitro Golgi membrane tubulation (Figure 2-1 F), whereas 
the addition of LIS1 antibodies had no effect (data not shown). These results 
show that PAFAH Ib catalytic activity is required for stimulating membrane 
tubules from isolated Golgi complexes.  
 
PAFAH Ib α1 and α2 Partially Localize to Golgi Membranes and Tubules 
  In mildly expressing cells, catalytically active HA-tagged α1 or α2 
(Figure 2-1 C) were found diffuse throughout the cytoplasm, in the nucleus, 
on punctate structures, and clearly on intracellular structures in the   
juxtanuclear region that co-localized with Golgi markers including Rab6-GFP 
(cis), GPP130 (cis), mannosidase II (ManII, medial), and mannose 6-phosphate 
receptors (M6PR, TGN)  (Figure 2-3 A, B; Figure 2-4; data not shown).  A 
similar distribution was seen by Caspi et al. in cells expressing GFP-α1 (356).  
Catalytically inactive α1 S47A and α2 S48A, as well as α1 E38D and α2 E39D,  
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Figure 2-1:  PAFAH Ib catalytic subunits are cytosolic Golgi tubulation factors.  
(A) Peak Golgi tubule-stimulating activity (determined by an in vitro 
reconstitution assay) co-fractionates with PAFAH activity and PAFAH Ib 
subunits (Western blot) in final bovine brain cytosol (BBC) fractionation steps.  
(data from Dr. Esther Racoosin)  (B) Silver stain of final fractions with the 
minimal components that stimulate Golgi tubules in vitro.  The components 
identified by MALDI TOF-TOF and/or Western blot are labeled (NS = non 
specific).  (Data shown from Dr. Anne Doody based on mass spec results from 
Dr. Kelvin Lee’s laboratory.)  (C) Coomassie-stained gel and PAFAH activity 
of purified subunits. (data from Dr. Anne Doody)  (D) EM of negative stain 
Golgi from in vitro tubulation reconstitution assays incubated with BBC and 
purified subunits as indicated.  Bars, 500 nm. (Images from M.E. Bechler) (E) 
Quantitation of tubulation assays using purified α1 and α2 subunits (7.5 
µg/ml), with subthreshold BBC (Low BBC, 0.25 mg/ml) compared to 
saturating BBC (1.5 mg/ml). svPLA2 = snake venom PLA2.  Results are the 
percentage of control (BBC), n = 4, error bars = SD. (Data shown from Dr. 
Anne Doody.)  (F) Anti-α1 and/or anti-α2 antibodies, but not pre-immune 
IgG (PI-α1, PI-α2), inhibit cytosol-stimulated Golgi membrane tubules in vitro.  
BSA = bovine serum albumin.  Results are percent of control (BBC),  
n = 4, error bars = SD.  (Data shown from Dr. Anne Doody.)  
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Figure 2-2:  α1 and α2 stimulate Golgi membrane tubules via catalytic activity, 
independently of LIS1 binding.  Quantification of isolated Golgi complexes 
with membrane tubules in the reconstitution assay.  Golgi were incubated 
with purified wild type or LIS1 binding-defective α1 E38D and α2 E39D (7.5 
µg/ml), in the presence or absence of Low BBC.  Results are percentage of 
control (BBC), n = 3, error bars = SEM. svPLA2 = snake venom PLA2. 
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Figure 2-3:  PAFAH Ib partially localizes to Golgi membranes.  (A) Confocal 
microscopy of BTRD cells mildly overexpressing α1 (HA tagged) and Rab6-
GFP.  Box indicates the region in lower panels. (B) Fluorescence intensity line 
plot of α1 and Rab6-GFP from the line shown in the merge image of lower 
panel of (A).  (C) Western blot showing α1 and LIS1 co-migrate with the Golgi 
(ManII) by sucrose-density cell fractionation.  Bracket indicates non-specific 
bands.  (D) Confocal slice shows HA-LIS1 localizes around the Golgi (ManII). 
(E) Line fluorescence intensity plot of LIS1 concentrated around Golgi 
complexes (from line in merge image of D).  Scale bars: A lower, E = 5 µm;  
A upper, D = 10 µm. 
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Figure 2-4:  Wild type and mutant α1 and α2 colocalize to multiple Golgi 
cisternae as well as the TGN.  Representative images of BTRD cells show the 
localization of α1, α2, α2 S48A catalytic mutant to medial Golgi, as seen by 
anti-ManII.  Representative image showing the double LIS1 binding mutant 
and catalytic inactive α1 S47A/E38D localizes to the TGN, as seen by anti-
M6PR.  Scale bars = 2 µm.   
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were similarly localized (Figure 2-4; data not shown), indicating that catalytic 
 activity and LIS1 binding are not required for α1 or α2 association with Golgi 
membranes.  In addition to centrosomal and cytoplasmic localization, HA-
tagged LIS1 was observed to surround the Golgi complex (Figure 2-3 D, E), 
consistent with reports that a small fraction of LIS1 is membrane associated 
(360).  PAFAH Ib α1 could also be found localized to membrane tubules 
(Figure 2-5).  Consistent with the imaging results, we found that a fraction of 
both α1 and LIS1 co-fractionated with Golgi membranes in sucrose gradients 
(Figure 2-3 C). 
 
PAFAH Ib α1 and α2 Overexpression Reveals a Connection Between PLA2 
Activity and LIS1-Mediated Regulation of Golgi Structure 
Overexpression of α1 or α2 resulted in a fragmented or completely 
dispersed Golgi and TGN (Figures 2-6; 2-7; 2-8), which was more severe in α2 
overexpressing cells (Figure 2-7 A, D, E).  Changes in Golgi structure were not 
observed when cells overexpressed an unrelated cytoplasmic PLA2, iPLA2α 
(E. Racoosin, data not shown).  Overexpression of catalytically inactive α1 
S47A or α2 S48A also caused the Golgi and TGN to become fragmented or 
diffuse (Figures 2-6; 2-7; 2-8).  Overexpression of catalytically inactive α1 or α2 
may produce a dominant negative effect by forming poisonous dimers, 
competing with endogenous α1 and α2 for binding to membranes, and/or by 
titrating LIS1, thus inhibiting the ability of LIS1 to regulate dynein (339, 367).   
Microtubules and dynein-mediated centripetal positioning are required for 
the maintenance of an intact mammalian Golgi near the centrosome (64).  To 
determine if overexpression of α1 and α2 affected Golgi structure by binding 
to and influencing LIS1 function, cells were transfected with the LIS1-binding 
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Figure 2-5:  α1 colocalizes with Golgi and TGN membrane tubules.  (A) α1 
(HA) localizes to Golgi tubules as seen in confocal images of BTRD cells.  
Arrowheads indicate colocalization with Rab6-GFP membrane tubules.  
(B) Line fluorescence intensity of α1 on membrane tubules (from line in merge 
image of A).  (C) Confocal stacks of BTRD cell overexpressing HA tagged α1 
PKD-KD-GFP shows α1 localizes to a subset of TGN tubules (arrowheads).  
Box indicates region shown in lower panel.   
Scale bars = 5 µm. 
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Figure 2-6:  Overexpression of PAFAH Ib alpha subunits perturbs Golgi and 
TGN structure.  (A) HeLa cells transfected with the indicated α1 (HA tagged) 
and double labeled for HA and either a Golgi (GPP130) or TGN marker 
(M6PR). Overexpression of α1 wild type, α1 S47A (catalytic mutant), or α1 
S47A/E38D (catalytic and LIS1 binding mutant) disrupted the structure of the 
Golgi and the TGN.  Asterisks and arrowheads indicate transfected and 
untransfected cells, respectively. (B) Quantitation of HeLa and BTRD cells 
with disrupted Golgi structure in cells transfected as indicated.  Weighted 
means shown, n = 3, error bars = SEM, *= p < 0.05 compared to untransfected 
cells, **= p< 0.001 compared to α1 E38D (Behrens-Welch test).  Scale  
bars = 10 µm. 
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Figure 2-7:  PAFAH Ib α1 and α2 disrupt Golgi structure. (A) Wide field 
fluorescence images showing HeLa cells overexpressing α2 (HA, *) wild type 
or mutants disrupt Golgi (GPP130) structure as compared to untransfected 
cells.  (B, C) Overexpression of α1 or α2 (HA, *) and indicated mutants, except 
a1 E38D, disrupt Golgi (ManII) structure, as compared to neighboring 
untransfected BTRD cells.  (D, E)  The severity of Golgi disruption was 
quantified in untransfected and overexpressing cells (as indicated), 
categorized as intact, fragmented, or diffuse Golgi, n = 3.  All scale  
bars = 10 µm. 
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Figure 2-8:  PAFAH Ib α1 and α2 disrupt TGN structure. (A) Wide field 
fluorescence images of HeLa cells overexpressing indicated constructs of α2 
(HA, *) disrupt TGN (M6PR) structure in comparison to untransfected cells.  
(B, C) Overexpression of the indicated α1 or α2 (HA, *) constructs, except α1 
E38D, disrupts TGN (M6PR) structure in BTRD cells.  All scale bars = 10 µm. 
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mutants α1 E38D or α2 E39D.  α2 E39D did disrupt the Golgi and TGN, albeit 
less severely than α2 wild type or α2 S48A (Figures 2-7; 2-8).  In contrast to 
wild type and catalytically inactive α1, overexpression of equivalent levels of 
α1 E38D did not significantly disrupt the Golgi or TGN (Figures 2-6; 2-7; 2-8; 
2-9), indicating that the Golgi disruption produced by α1 and α1 S47A are 
partially due to interactions with LIS1. 
To determine if catalytic activity of α1 and α2 is also important for 
maintaining Golgi structure in vivo, independent of LIS1, cells were 
transfected with a double mutant, which is both catalytically inactive and 
unable to bind LIS1 (α1 S47A/E38D; α2 S48A/E39D). These constructs also 
disrupted the Golgi and TGN (Figures 2-6; 2-7; 2-8). 
The LIS1 binding mutant results suggest that catalytic activity is 
important, and that α subunits also compete for binding to LIS1 to regulate 
dynein-dependent Golgi structure, in agreement with previous reports (338).  
In addition, our results agree with Ding et al., who found that overexpression 
of α2 had a more dramatic effect on Golgi positioning.  A role for LIS1 in Golgi 
structure has been suggested; LIS1+/- mouse embryonic fibroblasts had mild 
Golgi dispersal, and Cos-7 cells overexpressing LIS1 had more compact Golgi 
complexes (358).  
Our results suggest a model whereby PAFAH Ib provides a link 
between the initiation of membrane tubule formation and the subsequent 
movement of these tubules along microtubules. PAFAH Ib α1 and α2, bound 
to LIS1, may initiate membrane curvature by intrinsic PLA2 activity, thus 
forming membrane tubules.  Subsequently, LIS1 may switch to a LIS1-Ndel1-
dynein complex, facilitating the minus end movement of membrane tubules 
along microtubules to the centrosome (339).  This provides a mechanism to 
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couple the formation of Golgi membrane tubules to dynein motors for the 
formation and maintenance of a centrally located, intact Golgi ribbon. 
 
Loss of PAFAH Ib Fragments the Golgi Complex, Inhibits Tubule-Mediated 
Golgi Assembly, and Reduces Anterograde Trafficking 
To determine if PAFAH Ib α1 and α2 are required for Golgi structure and 
function, siRNA-mediated knockdown experiments were conducted.  PAFAH 
Ib α1 and α2 can form catalytically active homo- and heterodimers (323).  
Therefore we used mixed siRNAs targeting both α1 and α2, reducing 
expression by 85.7 + 3.3% and 81.8 + 3.8% (n = 7 and 6; + SEM), respectively, 
which did not affect levels of LIS1 (Figure 2-9).  As a consequence of α1 and α2 
loss, the Golgi complex, ER-Golgi-Intermediate Compartment (ERGIC), and 
the TGN became fragmented (Figures 2-10; 2-11).  Confocal microscopy 
revealed that fragmented Golgi puncta contained multiple cisternal markers, 
indicating that loss of α1 and α2 resulted in the formation of mini-stacks 
(Figure 2-10; 2-11), which was confirmed by transmission EM (Figure 2-10 D).  
Similar fragmentation was seen with knockdown of LIS1, which could be 
rescued by expressing RNAi-resistant HA-LIS1 (Figure 2-12), similar to other 
recent studies (360). 
Membrane tubule-mediated assembly and maintenance of an intact Golgi 
ribbon is inhibited by PLA2 antagonists (78).  To determine if knockdown of 
PAFAH Ib subunits similarly inhibits these tubules, we examined the 
reassembly of the Golgi during recovery from brefeldin A (BFA).  Following 
washout of BFA, the Golgi reassembles into separate mini-stacks that 
subsequently coalesce via membrane tubules into an intact ribbon (78).  
Knockdown of α1 and α2 or LIS1 had no apparent effect on BFA-stimulated  
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Figure 2-9:  Relative expression of α1.  (A) Western blot of α1 in control BTRD 
cells, BTRD cells overexpressing α1 and mutants, α1 & α2 siRNA treated cells 
or α1 & α2 knockdown cells expressing an RNAi-resistant α1 or α1 S47A.  (B) 
Relative expression levels—fold expression relative to endogenous—of α1 
when knocked down or overexpressed.  (C) Western blot of PAFAH Ib 
subunits in control and α1 and α2 siRNA treated (72 h) BTRD cells. 
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Figure 2-10:  PAFAH Ib subunits are important for maintaining an intact Golgi 
ribbon. (A) Confocal stack of the Golgi (ManII) in control BTRD and α1/α2 
siRNA transfected BTRD cells.  (B) The fraction of cells with fragmented 
Golgi.  n = 7, error bars = SEM, p < 0.001 by T-test.  (C) 3-D reconstructions of 
Golgi from confocal z-series of control and α1/α2 siRNA treated cells 
visualized with anti-ManII (medial marker, red) and GalT-GFP (trans marker, 
green).  (D) Electron micrographs from control and α1/α2 siRNA knockdown 
cells.  Scale bars: A = 2 µm; C, D = 500 nm. 
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Figure 2-11:  The ERGIC and TGN are perturbed in α1 and α2 knockdown 
cells, and the TGN is associated with mini-stacks.  Loss of α1 and α2 
fragments the ERGIC and TGN into mini-stacks. (A) Reduced α1 and α2 levels 
disrupts ERGIC structure. Control or α1 & α2 siRNA transfected BTRD cells 
transiently transfected with ERGIC53-GFP under a low expression promoter. 
(B)  Knockdown of α1 & α2 in BTRD cells fragments the TGN (M6PR). (C) The 
TGN in α1 & α2 siRNA transfected BTRD cells is present in mini-stacks, as 
seen by the overlap of M6PR (red) and expressed GalT-GFP (green) in 
confocal images.  Scale bars: A = 5 µm; B, C = 2 µm. 
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Figure 2-12:  Golgi structure is perturbed with LIS1 knockdown. (A) Western 
blot of LIS1 expression with siRNA knockdown and rescue 48 h after 
transfection of control BTRD cells, LIS1 siRNA transfected cells, and LIS1 
knockdown cells overexpressing RNAi resistant HA-LIS1. (B) Wide field 
fluorescence image of the Golgi (ManII) in control and LIS1 siRNA transfected 
BTRD cells. (C) Fraction of cells with fragmented Golgi.  n = 3, error  
bars = SEM.  Scale bars = 10 µm. 
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retrograde movement of Golgi enzymes to the ER (data not shown).  Upon 
washout, the emergence of separate Golgi mini-stacks was unaffected by 
knockdown of PAFAH Ib subunits.  In contrast, knockdown of α1 and α2 or 
LIS1 significantly inhibited subsequent coalescence into intact ribbons (Figure 
2-13; 2-14), which could be rescued by expressing RNAi-resistant LIS1 (Figure 
2-14 C, D).  Importantly, unlike α1 and α2 knockdown, LIS1 knockdown Golgi 
mini-stacks displayed numerous membrane tubules, which were no longer 
seen when all three subunits were knocked down (Figure 2-15).  These results 
are consistent with our in vitro and overexpression studies and further support 
the conclusion that the catalytic α1 and α2 subunits of PAFAH Ib are capable 
of inducing membrane tubules in vivo.  The membrane tubules that form in 
LIS1 knockdown cells are dependent on α1 and α2, but directed movement for  
mini-stack coalescence is inhibited in the absence of LIS1-mediated dynein 
interactions. 
In addition to reassembly of the Golgi complex, membrane tubules are 
implicated in export from the TGN and secretion (96, 97).  Using ts045VSV-G as 
a transmembrane cargo, we found that transport from the ER to the Golgi 
complex was unaffected in α1 and α2 knockdown cells (Figure 2-16).  In 
contrast, export of ts045VSV-G from the TGN to the cell surface was 
significantly slowed in α1 and α2 knockdown cells (Figure 2-17). VSV-G 
transport was unchanged with LIS1 knockdown (Figure 2-18), suggesting α1 
and α2 have LIS1-independent roles in TGN to plasma membrane trafficking.  
The reduced transport of VSV-G with α1 and α2 knockdown could be 
partially rescued by the re-introduction of equivalent levels of RNAi resistant 
α1, but not RNAi resistant α1 S47A, indicating the PLA2 activity is important 
for regulating the transport of Golgi to plasma membrane cargo (Figure 2-17  
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Figure 2-13:  Golgi ribbon reassembly is significantly delayed in α1 and α2 
knockdown cells.  (A) Confocal images of the Golgi (anti-ManII) before BFA, 
after 20 min in BFA (0 min), and 20, 45 or 90 min after BFA washout in control 
or α1 & α2 siRNA transfected cells. (B) Percent of cells with reassembled Golgi 
ribbons after BFA washout. n = 4, error bars = SEM, at 90 min p < 0.01 by a 
T-test.  Scale bars =10 µm. 
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Figure 2-14:  Golgi ribbon reassembly is impaired in LIS1 knockdown cells.  
(A) Wide field fluorescence images of the Golgi (anti-ManII) before BFA 
treatment, and after 0, 20, 45, or 60 min of BFA washout.  RNAi-resistant HA-
LIS1 expression is shown in insets (anti-HA).  (B) Percent of cells with 
reassembled Golgi ribbons, n = 3, error bars = SEM.  Scale bars =10 µm. 
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Figure 2-15:  α1 and α2, but not LIS1 are important for membrane tubules in 
Golgi reassembly.  (A) Confocal images of Golgi ministacks (anti-ManII) after 
30 min of BFA recovery for α1 & α2 siRNA or LIS1 siRNA, or α1/α2/LIS1 
siRNA (triple) treated BTRD cells.  LIS1 knockdown cells show extensive 
membrane tubules, which are not seen in α1 & α2 or triple knockdown cells.  
(B) Percent of cells with Golgi tubules after 30 min of BFA washout.   n=3,  
error bars = SEM.  Scale bars = 5 µm. 
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Figure 2-16:  α1 and α2 knockdown does not affect anterograde transport of 
ts045VSV-G from the ER to the Golgi.  Control and α1 and α2 siRNA treated 
BTRD cells were transfected with VSV-G-YFP.  VSV-G-YFP fluorescence in the 
Golgi after release from a 40°C block to 20°C.  Lines correspond to first order 
kinetic equations: control k = 0.10 ± 0.02 and siRNA k = 0.07 ± 0.02, ± SEM.  
Difference in kinetic constants was not statistically significant, p < 0.25 (T-test).  
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Figure 2-17:  PAFAH Ib α1 and α2 are important for the transport 
transmembrane cargo ts045 VSV-G-YFP.  (A) Confocal stacks of ts045VSV-G-
YFP after release from a 20°C TGN block in control, α1 & α2 siRNA 
transfected, and either α1&2 siRNA + RNAi resistant α1 or catalytic mutant 
α1 S47A transfected BTRD cells.  Insets show anti-HA, indicating α1 or α1 
S47A transfected cells.  (B) Fluorescence intensity of post-TGN VSV-G-YFP 
fluorescence after release from 20°C.  Lines correspond to first order kinetic 
equations, control k = 0.027 ± 0.005 and siRNA k = 0.013 ± 0.003, ± SEM,  
p < 0.05 (T-test).  (C) Fluorescence intensity of post-TGN VSV-G-YFP 
fluorescence after release from 20°C for control, α1 & α2 siRNA, and siRNA 
cells transfected with RNAi resistant α1 or α1 S47A (catalytic mutant).  A-C,  
n = 3-4, error bars = SEM.  Scale bars = 10 µm. 
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Figure 2-18:  VSV-G-YFP is transported from the Golgi to the plasma 
membrane in LIS1 siRNA treated BTRD cells with rates similar to control cells, 
as seen by wide field fluorescence.  Scale bars = 10 µm. 
 92 
 93 
A, C).  Likewise, secretion of soluble cargo, ssHRP, was significantly inhibited 
in α1 and α2 knockdown cells (Figure 2-19).  Thus, loss of α1 and α2 may 
directly decrease TGN to plasma membrane tubulo-vesicular carriers (96, 97). 
 Loss of α1 and α2 could also influence Golgi trafficking by affecting any 
number of components that require specific lipids for binding.  Export from 
the TGN requires protein kinase D (PKD), which binds to membranes via 
diacylglycerol (222).  A kinase dead (KD) version of PKD, which inhibits TGN 
tubule fission (97), is a convenient marker for PKD association with the TGN.  
In α1 and α2 knockdown cells, PKD-KD-GFP underwent redistribution from 
the TGN to the cytoplasm and plasma membrane (Figure 2-20 A).  The 
structure and function of the Golgi and TGN is also dependent on COPI 
vesicles, AP-1 clathrin coated vesicles, and microtubules; however, we found 
that knockdown had no discernable effect on β-COP, AP-1, or tubulin (Figure 
2-20 B, C).  Similarly, the COPII vesicle component Sec31 was unaffected 
(Figure 2-20 B).  These results suggest that α1 and α2 contribute to 
phospholipid remodeling that is important for PKD association with the TGN.  
 It is becoming clear that Golgi structure and membrane trafficking 
require constant and complex phospholipid remodeling.  In addition to 
PAFAH Ib, cPLA2α has recently been shown to influence the Golgi by 
regulating tubule-mediated, cis to trans, inter-cisternal trafficking.  
Interestingly, loss of cPLA2α can be compensated by PAFAH Ib α1 (256).  
cPLA2α was also shown to regulate export from the TGN (258).  Other recent 
studies found that another phospholipase, iPLA1γ, contributes to tubule-
mediated retrograde trafficking from the Golgi (260).  Although the molecular 
mechanisms are unclear, continual phospholipid remodeling by PLA1, PLA2, 
and lysophosphatidyl acyltransferase enzymes, such as LPAAT3/AGPAT3 
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Figure 2-19:  PAFAH Ib α1 and α2 are important for the transport soluble 
cargo.  Secretion of ssHRP-Flag in control and α1 & α2 siRNA treated BTRD 
cells.  Media HRP activity was measured and normalized to total HRP 
expression, expressed as a fraction of secreted HRP at 8 h in control cells.  The 
rates of secretion were: control = 0.121 ± 0.003, α1 & α2 siRNA = 0.068 ± 0.008, 
± SEM. n = 8, error bars = SEM. 
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Figure 2-20:  α1 and α2 knockdown does not affect vesicle coat protein or 
microtubule distribution but alters protein kinase D localization.  (A) The 
localization of vesicle proteins COPII (Sec31), COPI (β-COP), and AP1 clathrin 
(γ-adaptin) is unchanged by α1 & α2 knockdown, as seen by confocal 
microscopy.  (B) PKD kinase dead-GFP (PKD-KD-GFP) distribution is affected 
by α1 & α2 siRNA knockdown. (C) Microtubules (α tubulin) are unaffected 
with α1 & α2 knockdown.  Scale bars: A (except Sec31) = 5 µm;  
B, C, and Sec31 in A = 10 µm. 
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(239), may be critical for regulating the availability of curvature-altering lipids 
such as lysophospholipids, phosphatidic acid, diacylglycerol, and/or for the 
recruitment of other membrane trafficking proteins, such as PKD (240). 
 Our results demonstrate a novel role for PAFAH Ib PLA2α subunits, 
which appear to be multi-functional, regulating PAF signaling, LIS1 function 
in dynein-mediated processes, and, as shown here, the formation of 
membrane tubules and the function of the Golgi complex.  Our studies reveal 
a novel relationship of PAFAH Ib PLA2 activity with dynein-dependent 
processes that are coupled by LIS1 to regulate Golgi structure.  Additionally, 
our results show that α1 and α2 have a LIS1-independent role in export from 
the TGN. 
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CHAPTER 3 
 
PAFAH Ib Catalytic Subunits Have Distinct Roles in Maintaining Golgi 
Structure and Function 
 
Abstract 
Recent studies have shown that the phospholipase subunits of Platelet 
Activating Factor Acetylhydrolase (PAFAH) Ib, α1 and α2, partially localize to 
the Golgi complex and regulate its structure and function.  PAFAH Ib consists 
of homo- and heterodimers of α1 and α2, together with a third subunit, the 
dynein regulator LIS1.  Using siRNA knockdown of individual subunits, we 
find that α1 and α2 perform overlapping and unique roles in regulating Golgi 
morphology, assembly, and secretory cargo trafficking.  Knockdown of either 
α1 or α2 reduced secretion of soluble HRP, but neither single knockdown 
reduced secretion to the same degree as knockdown of both.  Knockdown of 
α1 or α2 also inhibited reassembly of an intact Golgi complex following 
recovery from brefeldin A to the same extent as knockdown of both α1 and 
α2.  Interestingly, transport of VSV-G was slowed with subunit knockdown 
but at different steps in the secretory pathway: reduction of α1 slowed TGN to 
plasma membrane transport, whereas α2 loss reduced ER to Golgi trafficking.  
Similarly, knockdown of either subunit alone disrupted the Golgi complex but 
with markedly different morphologies.  Finally, knockdown of α1, or double 
knockdown of α1 and α2, resulted in a significant redistribution of kinase 
dead protein kinase D from the Golgi to the plasma membrane, whereas loss 
of α2 alone had no such effect.  These studies reveal an unexpected complexity 
in the regulation of Golgi structure and function by PAFAH Ib.  
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Introduction 
A series of pharmacological studies originally suggested that cytoplasmic 
phospholipase A (PLA) activities regulate the structure and function of the 
Golgi complex (78, 242, 244, 249).  More recent studies have revealed an 
unexpectedly large number of cytoplasmic PLA enzymes involved in these 
processes, with a common theme of partial localization to the Golgi complex 
and functional regulation of the Golgi complex by controlling the shape and 
formation of cisternal membranes as well as transport carriers exiting the 
Golgi (256, 258-260).  The calcium-dependent enzyme cPLA2α was shown to 
translocate to the Golgi during times of increased secretory load.  It is also 
involved in forming membrane tubules that bridge between Golgi cisternae 
for intra-cisternal trafficking of secretory cargo and is implicated in export 
from the trans Golgi network (TGN) (256, 258).  An unrelated cytoplasmic 
phospholipase, iPLA1γ is located on cis Golgi and ERGIC membranes and is 
required for tubule-mediated, COPI- and Rab6-independent retrograde 
trafficking from the Golgi to the ER (260).  Recent studies have determined 
that a third, unrelated phospholipase, platelet activating factor 
acetylhydrolase Ib (PAFAH Ib), also regulates the functional organization of 
the Golgi complex (259).  PAFAH Ib regulates membrane tubule formation 
that leads to the coalescence of the Golgi complex into an intact ribbon 
structure and regulates export from the TGN.  Thus, at least three different 
PLA enzymes function at different domains of the Golgi to regulate its 
structure and function. 
In addition to its role in Golgi structure and function, PAFAH Ib appears 
to be a multifunctional enzyme with varied biological roles in cells.  It consists 
of homo- or heterodimers of two PLA2 subunits α1 and α2, and a third 
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subunit, LIS1/β (321, 331, 365).  PAFAH Ib was first discovered by its ability 
to hydrolyze the extracellular signaling lipid, PAF, which plays a role in 
platelet activation and inflammation (322).  LIS1/β, the causative agent of the 
fatal brain disorder Miller-Dieker lissencephaly, functions independently of 
the α subunits to regulate the activity of cytoplasmic dynein (339, 366, 367).  
Although the functional relationship between PAFAH Ib and LIS1/dynein is 
unclear, several studies strongly suggest that altering the cytoplasmic levels of 
α1 and α2 controls the amount of LIS1 that is available for functional 
interactions with dynein (259, 337, 338). 
Another area of uncertainty concerns the functional roles of the α1 and 
α2 subunits.  Human α1 and α2 are 63% identical at the amino acid level and 
can form catalytically active homo- and hetero-dimers (323).  However, 
numerous studies have established that α1 and α2 have differences in 
substrate preferences (323), catalytic rates when bound to LIS1/β (323), 
developmental expression patterns (325), and neurological phenotypes in 
different mutant backgrounds (370). 
Previous studies have suggested a role for PLA2 activity in regulating the 
formation of membrane tubules that facilitate cargo export from the Golgi 
complex and endosomes (242).  Using a cell-free in vitro reconstitution system 
and biochemical fractionation of bovine brain cytosol (369), we discovered 
that PAFAH Ib was able to induce tubule formation from Golgi membranes, 
and in vivo studies showed that α1 and α2 are partially localized to Golgi 
membranes (259).  Unable to find a cell line that expresses only one of the a 
subunits, we performed double knockdown experiments of PAFAH Ib α1 and 
α2 subunits, which resulted in the fragmentation of the Golgi/TGN ribbon 
into smaller, disconnected cisternal stacks (mini-stacks) and significantly 
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decreased export from the TGN.  However, these studies left the open 
question of the relative roles of α1 and α2 in regulating the functional 
organization of the Golgi complex.  Here we report that single knockdown of 
either α1 or α2 results in significant differences in Golgi morphology and 
function.  We conclude that α1 and α2 have overlapping and distinct functions 
in regulating the Golgi, which suggest an additional level of complexity for 
the role of these enzymes at the Golgi complex. 
 
Materials and Methods 
Reagents 
BFA and cycloheximide were from Biomol Research Laboratories, Inc.  
Antibodies and GFP-tagged constructs were obtained as follows: guinea pig 
anti-α1 antibody (by us (259)); chicken anti-α2 (Abcam, Inc.); mouse anti-HA 
(Covance); rabbit anti-dynamin (MC63) (M. McNiven, Mayo Clinic, Rochester, 
MN); rabbit anti-ManII (K. Moremen, Univ. of Georgia, Athens, GA); mouse 
anti-β-COP (BioMakor), mouse anti-α tubulin (Sigma Chemical Co.), rabbit 
anti-γ-adaptin (Santa Cruz), rabbit anti-Sec31A (W. Balch, Scripps Research 
Institute, La Jolla, CA) fluorescent secondary antibodies (Jackson Immuno-
Research Laboratories and Invitrogen); HRP-conjugated goat anti-chicken 
(Aves Laboratories), anti-guinea pig (Pocono Rabbit Farm and Laboratory), 
anti-rabbit (GE Healthcare), and anti-mouse (Gibco).  ERGIC53-GFP was from 
C. Fromme (Cornell University, Ithaca, NY); ts045 VSVG-YFP was from B. 
Storrie (University of Arkansas for Medical Sciences, Little Rock, AR); ssHRP-
Flag (in pEN1) and PKD-KD-GFP (in pEGFP) were from V. Malhotra (Centre 
de Regulació Genòmica, Barcelona, Spain).   
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Preparation of Plasmids  
An RNAi-resistant version of pEN1-α1-HA was generated as described 
in Chapter 2. 
 
Cell Culture, Transfection and RNAi  
BTRD bovine testicular were cultured in MEM (Mediatech, Inc.) with 
10% BGS in a 37°C, 95% humidity, and 5% CO2 incubator.  Double stranded 
RNA purchased from Thermo Scientific were: 
AGAAUGGAGAGCUGGAACAUU and GGAGAACUGGAGAAUAUUAUU, 
for α1 and α2, respectively (8).  The control double stranded RNA was 
siGenome non-targeting siRNA #1 and #2 from Thermo Scientific.  30 nM of 
RNA was transfected on two consecutive days with Lipofectamine RNAiMax 
(Invitrogen).  DNA transfection was carried out 48 h after the first RNA 
transfection, using Lipofectamine 2000 (Invitrogen) with ¼ the amount of 
reagent and DNA indicated by the manufacturer.  Experiments were 
conducted 72 h after the initial RNA transfection.   
 
Cell Lysates and Immunoblotting 
 Cells were lysed by scraping dishes in the presence of 0.05% TritonX-
100 in phosphate buffered saline, pH 7.4 and complete protease inhibitor 
cocktail (Roche Applied Science).  Lysates and purified proteins were run by 
SDS-PAGE, transferred to PVDF membranes, and Western blotted with the 
following antibodies: guinea pig anti-α1 (1:2,000); chicken anti-α2 (1:1000); 
Detection rabbit anti-dynamin (1:10,000) was used as an internal loading 
control.  HRP-conjugated antibodies were: goat anti-guinea pig (1:2,500); goat 
anti-chicken (1:2,500); and goat anti-rabbit (1:10,000).  HRP was detected with 
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Millipore Corporation enhanced chemilluminescent reagent.  Band intensities 
were quantified using NIH ImageJ software, background intensity was 
subtracted, and normalized to the corresponding anti-dynamin band for each 
lane.  
 
Fluorescence Microscopy  
For direct fluorescence of GFP or YFP tagged proteins, cells were fixed in 
3.7% formaldehyde in PBS for a minimum of 10 min at room temperature, 
washed in PBS three times for 5 min each, mounted with Vectashield (Vector 
Laboratories) mounting media, and stored at -20oC until imaged.   For 
immunofluorescence, cells were fixed in 3.7% formaldehyde in PBS for a 
minimum of 10 min at room temperature, washed in PBS for 5 min three times 
and permeabilized with 0.1% Triton X-100 in PBS for 10 min.  Cells were then 
incubated for one hour at room temperature or overnight at 4oC with primary 
antibodies diluted in PBS, followed by three washes in PBS and secondary 
antibody incubation for 1 h at room temperature.  Coverslips were mounted 
with Vectashield (Vector Laboratories) mounting media, stored at -20oC until 
imaged.  Primary antibodies were diluted as follows: anti-HA, anti-Sec31A 
anti-ManII, anti-β-COP, anti-α tubulin, and anti-γ-adaptin 1:100.  Secondary 
antibodies conjugated to Alexa 488, DyLight 488, fluorescein isothiocyanate, 
or tetramethylrhodamine isothiocyanate were used, diluted in PBS 1:500 for 
Alexa488 and 1:100 for all other secondary antibodies.  Wide-field 
epifluorescence images were taken with a Zeiss Axioscope II, a Zeiss 40x Plan-
Apochromat NA1.4 oil objective lens, a Hamamatsu Orca II digital camera, 
and Openlab software (Improvision).  Spinning disk confocal images were 
taken with a Nikon Eclipse TE2000-U, a Nikon Plan-Apo 60xA/N1.4 or Nikon 
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Plan-Apo100x/N1.4 oil objectives, with Perkin-Elmer Ultraview LCI, a 
Hamamatsu 1394 ORCA-ER camera, and Perkin-Elmer Ultraview software.  
 
Electron Microscopy 
Cells were fixed in a culture dish using 1.5% glutaraldehyde fixative, 
containing 5% sucrose and 0.1 M Na cacodylate for 1 h, followed by three 15 
min 4oC 0.1 M Na cacodylate washes, and post-fixing in osmium tetroxide (1% 
OsO4, 1% KFeCN, 0.1 M Na cacodylate) for 1h at 4oC.  Cells were washed in 
4oC 0.1 M sodium cacodylate three times for 15 min followed by staining with 
0.25% uranyl acetate for 30 min, and an additional three sodium cacodylate 
washes.  Cells were dehydrated using sequential 70%, 95%, and 100% ethanol 
washes and removed from the dish by scoring and propylene oxide.  Cells 
were pelleted in a centrifuge, infiltrated for 30 min with equal part mixture of 
Spurs and propylene oxide, which was replaced with 100% Spurs overnight.  
The Spurs was replaced twice more and polymerized at 60°C for 24 h. For 
electron microscopy images, a FEI Morgagni 268 transmission EM was used. 
 
VSV-G-YFP and ssHRP-Flag  
The pixel intensities of ts045 VSV-G-YFP for entire cells and the 
juxtanuclear Golgi region were measured from confocal images using ImageJ 
(NIH), with background fluorescence subtraction (per area).  For ssHRP-Flag 
measurements, HRP activity was quantified by absorbance using 3, 3’, 5, 5’-
tetramethylbenzidine reagent from Sigma (TMB).  Collected media and cell 
lysates were used for measurements, which were normalized to total HRP 
expression (total activity in the media + lysate).  All reactions with TMB were 
done in duplicate or triplicate and the absorbencies were measured at 450 nm 
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with a SpectraMax 190 (Molecular Devices) 96-well plate reader.  
 
Image Analysis and Statistics 
For experiments, > 100 cells were counted for each condition, and each 
experiment was repeated independently > three times.  The statistical 
significance between control and knockdown cells was determined with a 
two-tailed, unequal variance T-test. Images and z-projections were cropped, 
brightness adjusted, or contrast adjusted using ImageJ or Photoshop CS3. 
 
Results 
Knockdown of α1 or α2 Subunits Fragments the Golgi Complex with 
Dramatically Different Morphologies 
To examine the contribution of individual PAFAH Ib catalytic subunits 
to regulation of Golgi structure, we performed single knockdown studies of 
α1 or α2.  Cultured BTRD cells express PAFAH Ib α1 and α2 subunits at 
approximately equal levels, composing 0.025-0.05% of the total soluble protein 
weight (Figure 3-1).  Knockdown of either α1 or α2 alone resulted in a 
significant loss of the appropriate subunit but not the other (Figure 3-2).  
Similar to double knockdown, loss of either α1 or α2 resulted in fragmentation 
of the Golgi ribbon but with qualitatively different morphologies.  As 
visualized by immunofluorescence with the medial marker α-mannosidase II 
(ManII), the Golgi in α1 knockdown cells were often dilated, ranging from 
distinct rounded fragments to web-like or highly fenestrated membranes, 
although still clustered in the juxtanuclear region (Figure 3-3; 3-4).  Thin  
section transmission electron microscopy (TEM) revealed that the fragments 
seen by fluorescence microscopy were relatively a normal stacked (mini-stack) 
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Figure 3-1:  Relative endogenous expression of α1 and α2 in BTRD cells.  
Western blots of α1 and α2 from BTRD cell lysate (soluble proteins) compared 
to either α1 or α2 purified protein dilutions.  The approximate total protein 
loaded in each lane is indicated. 
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Figure 3-2:  siRNA-treated BTRD cells with siRNAs targeting either α1 or α2 
siRNA show appropriate subunit reduction.  Western blots showing amounts 
of α1 and α2 in control, single, or double siRNA-treated BTRD cells 72 h after 
initial siRNA transfection.  Dynamin served as a loading control. 
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Figure 3-3:  Single knockdown of either PAFAH Ib α1 or α2 causes differential 
fragmentation of the Golgi complex.  (A) Confocal z-series of the Golgi (anti-
ManII immunofluorescence) and direct fluorescence of ERGIC53-GFP (B) in 
control, single, and double knockdowns.  Two images of α1 siRNA-treated 
cells are shown for anti-ManII to demonstrate the range in phenotype.  Scale 
bars = 5 µm.  (C) Transmission electron microscopy of thin sections from 
control and single knockdown BTRD cells.  Scale bars = 500 nm. 
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Figure 3-4:  Organelle morphologies in single knockdown.  Additional wide-
field and EM micrographs illustrating the range in Golgi and ER 
morphologies following single knockdown of either PAFAH Ib α1 or α2.   
Scale bars = 2 µm and 500 nm (EM). 
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 structure but with obviously dilated cisternae (Figure 3-3; 3-4).  In contrast, 
Golgi fragments in α2 knockdown cells appeared as short linear and punctate 
or vesiculated elements by immunofluorescence (Figure 3-3; 3-4).  By TEM, 
these fragments were also part of mini-stacks but with cisternae that appear to 
be significantly vesiculated (Figure 3-3).  Strikingly, α2 knockdown cells also 
exhibited fairly dilated ER morphology as seen by EM (Figure 3-4).   
Knockdown of α1 or α2 appeared to have a less dramatic effect of ER-
Golgi-Intermediate Compartment (ERGIC) fragmentation as seen by 
localization of ERGIC53-GFP in comparison to α1 and α2 knockdown but still 
appeared more fragmented than control cells (Figure 3-3 B).  Additionally, α2 
knockdown cells appeared to have a higher proportion of ERGIC53-GFP 
fluorescence in ER-like structures compared to control and other knockdown 
cells (Figure 3-3 B).  
 
Reduced α1 or α2 Levels Slow Secretory Trafficking But at Different Steps of 
the Pathway 
Loss of both α1 and α2 inhibits transport through the secretory pathway, 
at least at the level of export from the TGN (259).  To determine the relative 
contribution of each subunit, knockdowns of individual subunits were 
performed, revealing an unexpected difference between the two with regard 
to secretory trafficking.  When measuring bulk soluble protein transport 
through the secretory pathway, by assaying soluble secreted HRP (ssHRP) in 
transfected cells, knockdown of either α1 or α2 resulted in a loss of secretion 
that was approximately 50% that of double knockdown (Figure 3-5 A).  To  
more accurately assess the location of secretory protein trafficking inhibition 
by α1 or α2 knockdown, we employed the ts045 VSV-G-YFP protein. 
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Figure 3-5:  Secretory protein trafficking is inhibited at different steps in single 
PAFAH Ib α1 or α2 knockdown cells.  (A) Kinetics of ssHRP secretion, 
measured by HRP activity in the media of control or siRNA-treated (as 
indicated) BTRD cells.  Values were normalized to expression levels of HRP 
and HRP activity in control cells at 8 h.  (B) Confocal images of ts045 VSV-G-
YFP transport in single knockdown cells.  Transfected cells were incubated at 
40°C to accumulate ts045 VSV-G-YFP in the ER, shifted to 20°C for 20 or 120 
min to allow export from the ER and transport to the TGN, and then shifted to 
32°C for 80 min to allow export from the TGN and transport to the cell 
surface.  (C) Quantification of the percent of total ts045 VSV-G-YFP 
fluorescence on the PM following shift to 32°C for 80 min.  For α2 knockdown 
cells, only cells with VSV-G outside the ER (~80% of cells) were measured. 
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 ts045 VSV-G-YFP was allowed to accumulate in the ER at the restrictive 
temperature (40°C), shifted to 20°C to allow export from the ER and 
accumulation in the TGN, and then shifted again to the permissive 
temperature (32°C) to allow export from the TGN and delivery to the cell 
surface.  In control cells, ts045 VSV-G clearly accumulated in the intact, 
ribbon-like TGN by 120 min following shift to 20°C, and was then delivered to 
the plasma membrane following shift to 32°C for 80 min (Figure 3-5 B).  In α1 
knockdown cells, ts045 VSV-G similarly accumulated in the fragmented TGN 
and was significantly slowed in export and delivery to the plasma membrane 
following shift to 32°C (Figure 3-5 B, C).  This inhibition was rescued by 
expression of siRNA-resistant α1 construct after knockdown (Figure 3-5 C).  In 
contrast to α1, knockdown of α2 resulted in a significant inhibition of ts045 
VSV-G reaching the TGN following shift to 20°C, and a prolonged presence in 
the ER (Figure 3-5 B).  After 120 min at 20°C ~40% of α2 siRNA-treated cells 
had a substantial amount of VSV-G in the ER.  However, once in the TGN, 
transport to the plasma membrane was not noticeably slowed (compare 
control versus α2 siRNA at the 80 min time point) (Figure 3-5 B, C).  Even at 80 
min following shift to 32°C, ~15-20% of cells still had VSV-G in the ER.  Thus, 
it would appear that α1 and α2 affect different trafficking steps to regulate 
transport dynamics.   
 
Knockdown of α1 or α2 Does Not Affect Coat Protein Localization But Has 
Differential Effects on the Localization of Protein Kinase D 
We previously found that knockdown of both α1 and α2 did not 
significantly impact the localization of various trafficking proteins such as the 
COPI subunit β-COP, clathrin AP-1 adaptor, or the COPII subunit Sec31 (259).  
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Likewise, single knockdown did not influence these markers (Figure 3-6 A).  
Protein kinase D (PKD) is a regulator of TGN secretory vesicle fission (97).  A 
kinase dead version of PKD (PKD-KD) localizes to the TGN and induces a 
dominant negative effect on vesicle fission thereby causing the formation of 
extensive membrane tubules (371).  We found that double knockdown 
appeared to inhibit PKD-KD-induced TGN tubule formation, and resulted in a 
significant relocation of PKD-KD from the TGN to the plasma membrane (259) 
(Figure 3-6 B).  Interestingly, cells subjected to single knockdown of α1, but 
not α2, exhibited a similar phenotype (Figure 3-6 B).  Thus, α1 subunits alone 
play a role in maintaining PKD-KD at the TGN. 
 
Both α1 and α2 Are Required for Assembly of an Intact Golgi Ribbon 
In addition to secretory trafficking, PLA2 activity controls the biogenesis 
and maintenance of an intact Golgi ribbon.  Biogenesis of the Golgi complex 
has often been studied using recovery from brefeldin A (BFA) treatment as a 
model system (78), and we have previously shown that knockdown of both α1 
and α2 inhibits the coalescence of mini-stacks into an intact ribbon (259).  
Similarly, following knockdown of either α1 or α2 and recovery from BFA 
treatment, the Golgi complex reassembled into separate mini-stacks, but their 
coalescence into intact ribbons was inhibited (Figure 3-7 A, B).  In each case, 
the Golgi reassembled into mini-stacks during recovery from BFA, but the 
Golgi did not form intact ribbon morphology (Figure 3-7), demonstrating that 
reassembly of the Golgi requires both subunits. 
 
Discussion  
 In previous studies, we found that double knockdown of the two 
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Figure 3-6:  Localization of vesicle markers and protein kinase D in single 
knockdown cells.  (A) Knockdown of PAFAH Ib α1 or α2 does not detectably 
affect clathrin AP-1 adaptor, COPI subunit β-COP, or the COPII subunit 
Sec31a in BTRD cells.  Scale bars = 5 µm.  (B) Knockdown of α1, but not α2, 
causes a loss of PKD-KD-GFP from the TGN and redistribution to the plasma 
membrane.  Scale bars = 10 µm. 
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Figure 3-7:  Golgi reassembly following BFA washout is inhibited in PAFAH 
Ib α1 or α2 single knockdown cells.  (A) Confocal images of control and cells 
treated with siRNA against individual or both subunits.  BTRD cells were 
treated with media containing 5 µg/mL BFA for 20 min, followed by 
replacement with BFA-free media to allow reassembly of the Golgi.  Cells 
were fixed at the indicated time points (after BFA removal) and processed for 
immunofluorescence with anti-ManII.  Scale bars = 10 µm.  (B) Quantification 
of reassembly into an intact Golgi ribbon in control and siRNA-treated cells.  
(C) Confocal micrographs illustrating the morphology of the Golgi complex 
(anti-ManII immunofluorescence) during recovery from BFA in control and 
siRNA treated cells.  Scale bars = 2 µm. 
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catalytic subunits of PAFAH Ib, α1 and α2, produced a severely fragmented 
Golgi and inhibited secretion (259).  Here we examine α1 and α2 subunits 
individually and show that these subunits play overlapping but also distinct 
roles in regulating Golgi structure and function.  This is a surprising result 
because α1 and α2 can form both functional homo- and heterodimers, all of 
which form competent complexes with LIS1 (323). 
 Loss of either α subunit produces distinctly different Golgi 
morphologies: the Golgi complexes in α1 knockdown cells are swollen and 
highly fenestrated, whereas α2 knockdown cells exhibit a severe vesiculated 
phenotype.  Interestingly, the Golgi morphologies in single knockdown cells 
are not exactly the same as those in double knockdown cells, in which the 
fragmented Golgi complexes do not show the same degree of cisternal dilation 
or vesiculation (259).  These results strongly suggest that Golgi morphology 
requires a tight balance between the levels of both α1 and α2 subunits.  The 
reason for the differences in single knockdown cells is not clear.  One 
possibility could be based on the fact that α2 appears to have a higher affinity 
for LIS1 (based on the relative abilities of α1 and α2 to compete with Ndel for 
binding to LIS1) (338).  These differences are likely relevant in vivo for 
regulation of LIS1 and dynein function; however, cells with reduced α2 have 
smaller, vesiculated Golgi and more dilated ER, which is not consistent with 
α2 knockdown simply effecting dynein activation.  Dynein activity is 
important for anterograde ER to Golgi trafficking (179), which hypothetically 
should increase in the absence of α2 competition for binding LIS1.  On the 
contrary, α2 knockdown phenotypes suggest decreased ER to Golgi transport.  
A second possibility to explain differing phenotypes between α1 and α2 
knockdown is by their relative substrate preferences.  In vitro studies suggest 
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that heterodimers and α1/α1 homodimers are more selective for phosphatidic 
acid (1-O-alkyl-2-acetyl-3-sn-glycero-phosphoric acid) species and exhibit little 
to no activity on phosphatidylethanolamine, whereas α2/α2 homodimers 
have much lower phosphatidic acid catalytic activity and had preference for 
platelet activating factor, a phosphatidylcholine derivative (1-alkyl-2-acetoyl-
sn-glycero-3-phosphocholine), and phosphatidylethanolamine species (1-O-
alkyl-2-acetyl-3-sn-glycero-phosphorylethanolamine) (323).  The generation of 
distinct lysophospholipid species may help to account for changes in 
membrane architecture by changing membrane shape and/or feeding into 
different lipid metabolic pathways (159, 240).    
 Loss of either α1 or α2 inhibited soluble protein secretion to ~50% that 
achieved by double knockdown, initially suggesting that each has overlapping 
functions in secretion.  However, the second surprising finding was that α1 or 
α2 appear to facilitate protein trafficking at different stages of the secretory 
pathway—loss of α2 resulted in slowed export from the ER and delivery to 
the TGN, whereas loss of α1 inhibited binding of PKD-KD to the TGN and 
export from the TGN.  These observations are consistent with previous 
pharmacological studies showing that PLA2 antagonists have similar effects 
on ER and TGN export (372).  This result is also consistent with the dilated ER 
and Golgi morphologies for α2 and α1 knockdown, respectively.  These 
results strongly suggest that α2 homodimers function early in the secretory 
pathway and α1 homodimers later.  Moreover, it is possible that these 
different effects on trafficking could be indirectly related to the differences in 
Golgi morphology produced by single knockdowns.  Our localization studies 
of expressed subunits are not helpful in this regard because we observed no 
significant difference in the intracellular distributions of α1 and α2, with both 
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being cytosolic, nuclear, and Golgi-associated (259).  
 PAFAH Ib α1 and α2 subunits both have profound effects on secretory 
trafficking, Golgi structure, and the assembly of the Golgi complex.  BFA 
washout studies show that reduced levels of either subunit delays the 
reassembly of an intact Golgi ribbon to the same extent as knockdown of both 
subunits.  Interestingly, α2 knockdown, while having an effect on cargo export 
from the ER does not show an observable difference in the appearance of 
Golgi mini-stacks from the ER.  Instead, either α1 knockdown or α2 
knockdown inhibits reassembly at the stage of mini-stack coalescence into 
Golgi ribbon morphology, a stage that has been observed to require dynein-
mediated membrane tubule transport (78, 79).   
 Importantly, cells did not compensate for single knockdowns by 
increasing expression of the other subunit.  Even though single knockdowns 
still expressed wild type levels of the other subunit, it was not enough to 
overcome the loss of one subunit.  Thus, the overall functional organization of 
the Golgi is very sensitive to total α1 and α2 levels. 
 Work from several laboratories in the past year has revealed an 
unexpected level of complexity with regard to phospholipase regulation of the 
Golgi complex.  In addition to PAFAH Ib, two other phospholipases have 
recently been shown to regulate different aspects of Golgi structure and 
function.  These include iPLA1γ, which regulates retrograde trafficking to the 
ER (260), and cPLA2α, which regulates tubule-mediated, cis to trans, inter-
cisternal trafficking (256) as well as export from the TGN (258).  Our studies 
here strongly suggest that PAFAH Ib α1 and α2 homodimers have some 
distinct functions, indicating that the Golgi is influenced by four 
phospholipases.  The extent to which these phospholipases function 
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independently to control Golgi structure and function is unclear.  Although, 
previous studies indicate that loss of cPLA2α can be compensated by PAFAH 
Ib α1: VSV-G trafficking in cells from cPLA2α-/- mice is only decreased with 
the additional reduction of α1 levels by RNAi (256).  It is evident that future 
studies will be required to dissect the individual and combined roles of these 
enzymes. 
The molecular mechanisms by which PAFAH Ib, iPLA1γ, or cPLA2α 
regulate the functional organization of the Golgi complex is unclear.  The 
combined evidence strongly suggests that all three can influence the shape of 
Golgi membranes by controlling membrane tubule formation.  Moreover, it 
would appear that continual phospholipid remodeling by PLA1, PLA2, and 
lysophospholipid acyltransferase enzymes, such as LPAAT3/AGPAT3 (239), 
may be critical for regulating the availability of curvature-altering lipids such 
as lysophospholipids, phosphatidic acid, diacylglycerol, and/or for the 
recruitment of other membrane trafficking proteins, such as PKD and vesicle-
associated coat proteins (240). 
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CHAPTER 4 
 
PAFAH Ib Regulates Endosome Positioning, Membrane Tubule Formation 
and Transferrin Recycling 
 
Abstract 
Previous studies have shown that membrane tubule-mediated export 
from endosomal compartments requires a cytoplasmic phospholipase A2 
(PLA2) activity.  Here we report that the catalytic subunits of Platelet 
Activating Factor Acetylhydrolase (PAFAH) Ib, α1 and α2, which are 
cytoplasmic Ca2+-independent PLA2 enzymes, are located on early sorting 
endosomes and the central endocytic recycling compartment (ERC).  
Overexpression of catalytically active α1 and α2, but not their catalytically 
inactive counterparts, induced endosome membrane tubules.  In addition, 
overexpression α1 and α2 altered normal endocytic trafficking; transferrin was 
recycled back to the plasma membrane directly from peripheral early sorting 
endosomes, instead of making an intermediate stop in the ERC.  Consistent 
with these results, siRNA-mediated knockdown of α1 and α2 significantly 
inhibited the formation of endosome membrane tubules and delayed the 
recycling of transferrin.  Additionally, our results agree with previous reports 
that PAFAH Ib α1 and α2 expression levels affect the distribution of 
endosomes within the cell through interactions with the dynein regulator 
LIS1.  These studies characterize a novel PLA2-dependent mechanism for 
mediating endocytic membrane trafficking and identify a function for PAFAH 
Ib in this process. 
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Introduction 
Trafficking through the endocytic pathway involves an ordered set of 
transport steps that move both membrane-bound and soluble cargo between 
different compartments (24, 115).  In mammalian cells, most endocytic 
compartments, especially early sorting endosomes and the endocytic recycling 
compartment (ERC), are morphologically complex tubulo-vesicular structures, 
consisting of a mosaic of phosphoinositides, regulatory proteins, and other 
effectors (115, 175, 373, 374).  Sorting and export out of endocytic 
compartments has long been recognized to involve membrane tubules that 
emanate from the main vacuolar domain (193).  Based on geometry alone, thin 
membrane tubules (60-80 nm in diameter) serve as efficient sorting structures 
to separate membrane lipids and proteins from soluble internal contents (195).  
Early studies showed that many itinerant receptors become concentrated into 
tubular domains of endosomes for efficient export (126, 127, 375).  These 
tubular extensions may function as platforms for the budding of coated 
vesicles or may detach to serve as trafficking intermediates (152). 
 The molecular mechanisms that mediate the formation of endosome 
membrane tubules are unclear.  Rabs and other molecules have been shown to 
be involved in the formation of tubular domains on endosomes and to 
function in export from these organelles.  For example, sorting nexins (SNX) 
(148) and Rab7 (376) facilitate the tubule-mediated sorting of itinerant 
endocytic cargoes.  In addition, pharmacological and biochemical studies have 
suggested that phospholipid remodeling by cytoplasmic phospholipase A2 
(PLA2) enzymes plays an important role in the formation of endosome 
membrane tubules (242).  For example, a broad spectrum of PLA2 antagonists 
inhibit the formation of endosome membrane tubules in vivo and in a cytosol-
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dependent in vitro reconstitution system (245).  In addition, these PLA2 
antagonists inhibit the export of transferrin (Tf) and Tf receptors (TfR) from 
early sorting endosomes and the ERC.  These results strongly suggest that a 
cytoplasmic PLA2 functions in tubule-mediated export at each of these 
endosomal compartments. 
The identity of cytoplasmic PLA2 enzymes involved in the formation of 
endosomal membrane tubules has remained elusive.  Here we show that the 
catalytic subunits of platelet activating factor acetylhydrolase (PAFAH) Ib are 
endosome-associated PLA2 enzymes that mediate tubule formation and 
routing endocytic receptors for recycling.  PAFAH Ib was originally purified 
based on its ability to hydrolyze an acetyl group in the sn-2 position of the 
signal transduction phospholipid, platelet activating factor (PAF) (322).  It is a 
multi-subunit complex consisting of a dimer of two highly conserved catalytic 
subunits, α1 (Pafah1b3) and α2 (Pafah1b2), and an associated non-catalytic 
subunit, β (Pafah1b1) (302).  Within a species, α1 and α2 subunits share ~60% 
amino acid identity and by themselves can form catalytically active homo- or 
heterodimers (323).  The β subunit, also known as LIS1, is highly conserved 
from yeast to humans, and mutations in it lead to the fatal brain disorder 
Miller-Dieker lissencephaly (366).  Recent studies have shown that, 
independent of binding to α1 or α2, LIS1/β regulates the location of dynein on 
microtubules through the combined activities of a host of accessory proteins 
including NudE, and NudEL (377).  LIS1/β, NudE, and NudEL are 
responsible for cytoplasmic nuclear trafficking in yeasts, spindle orientation, 
and neuronal migration in mammals, the latter being compromised in human 
lissencephaly (339, 367).  
Although PAFAH Ib has been implicated in a wide array of processes, its 
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exact biological function is unclear.  Mice with targeted disruption of both 
Pafah1b2 and Pafah1b3 genes (α1-/-/α2-/-) exhibit defects in spermatogenesis 
but are otherwise normal (326, 330).  In contrast, recent studies using 
overexpression and siRNA-mediated knockdown of α1 and α2 in cultured 
cells showed that PAFAH Ib α1 and α2 function to mediate the functional 
organization of the Golgi complex and secretion (256, 259).  These results 
show that PAFAH Ib has an unexpected role in intracellular membrane 
trafficking.  Here we show that this role is not limited to secretion.  We found 
that α1 and α2 are partially localized to endosomes and that overexpression of 
either subunit induces endosome membrane tubule formation and alters the 
recycling route of endocytosed Tf and TfRs.  Conversely, siRNA-mediated 
knockdown of α1 or α2 in cultured cells inhibited endosome tubule formation 
and delayed the recycling of Tf.  These results demonstrate a novel 
mechanism for mediating endosome membrane trafficking and a new 
physiological role for PAFAH Ib enzymes. 
 
Materials and Methods 
Reagents 
Brefeldin A (BFA) was obtained from Biomol Research Laboratories, Inc.  
The stock solution of BFA (10 mg/mL in ethanol) was stored at -20°C and 
diluted to working concentrations of 5 µg/mL in MEM just prior to use.  
Alexa 488-Tf (Molecular Probes) and bovine holo-transferrin were purchased 
from Invitrogen.  Fluorescein isothiocyanate (FITC) was from Sigma.   
Mouse monoclonal anti-human influenza virus hemagglutinin (HA) 
was purchased from Covance.  Rabbit polyclonal anti-early endosomal 
antigen 1 (EEA1) was purchased from Affinity Bioreagents and Cell Signaling.  
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Mouse anti-human transferrin receptor was obtained from Boehringer-
Mannheim and Zymed (Invitrogen).  Rabbit polyclonal and mouse 
monoclonal antibodies against the late endosome/lysosome marker CD63 and 
rabbit anti-Cathepsin D were prepared and characterized as described (378-
380).  The secondary fluorescent antibodies goat anti-mouse or goat anti-rabbit 
conjugated to FITC, TRITC, Cy5 or DyLight were purchased from Jackson 
ImmunoResearch Laboratories.  The anti-mouse conjugated to Alexa488 was 
from Molecular Probes (Invitrogen).  
 
Plasmids for Mammalian Expression  
PAFAH Ib plasmids were prepared as described in chapter 2.  Human 
cDNA of Rab11 and Rab4 in pEGFP vectors, GFP-Rab11 and GFP-Rab4, were 
the kind gifts of Dr. M. Scidmore (Cornell University).  Human Rab5A cDNA 
in the pGreenLantern vector, GFP-Rab5, was the gift of Dr. C. Roy (Yale 
University).  
 
Cell Lysates and Immunoblotting 
        Lysate preparation and immunoblotting was conducted as described in 
chapter 3. 
 
Cell Culture, Transfection, and Immunocytochemistry 
HeLa and BTRD cells were cultured and transfected as described in 
chapter 2.  Cells were processed for indirect immunofluorescence as described 
in chapter 3.  Primary antibodies used were diluted as follows in PBS: 
monoclonal mouse anti-HA at 1:100; polyclonal rabbit anti-EEA1 at 1:100 
(ABR) or 1:50 (Cell Signaling); monoclonal anti-TfR at 1:200; polyclonal rabbit 
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or mouse monoclonal anti-CD63 at 1:200; and polyclonal rabbit anti-Cathepsin 
D at 1:200.  Secondary antibodies were used at the following dilutions: FITC-, 
TRITC-, or Cy5-labeled anti-mouse IgG or anti-rabbit IgG at 1:100; Alexa 488-
labeled anti-mouse IgG at 1:500; and DyLight anti-rabbit at 1:100.  
 
Transferrin Preparation and Trafficking Experiments 
For use in BTRD cell experiments, bovine holo-transferrin was 
conjugated to FITC.  A 257 µM solution of FITC was made in 50 mM borate 
buffer, pH 9.2.  A 4 mg/mL transferrin solution was made in 5 mL of 50 mM 
borate buffer and was placed into dialysis tubing.  The dialysis tubing 
containing Tf was kept in the FITC solution at 4oC for 24 h.  The FITC-Tf in 
dialysis tubing was then placed in 3 L PBS, pH 7.4 at 4oC.  The PBS was 
exchanged 6 times over three days.  The resulting FITC-Tf was stored in 
aliquots at 4oC and spun briefly by low speed centrifugation before use. 
For Tf experiments, HeLa cells or BTRD cells were grown on coverslips 
for a minimum of two days, washed 15 min three times in 37oC MEM or 
DMEM without serum, and incubated for the indicated pulse time points with 
40 µg/mL FITC-Tf in 37oC MEM or DMEM.  Cells were then washed three 
times in 37oC MEM + 10% BGS, with subsequent incubation for chase time 
points.   FITC-Tf florescence was measured from 40x Zeiss wide-field images 
using ImageJ (NIH) to measure cell total fluorescence intensity, central (ERC) 
fluorescence intensity and background fluorescence.  For each image, the 
background fluorescence intensity (per pixel) was subtracted from the 
corresponding cell fluorescence measurements.   
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Microscopy 
Wide-field epifluorescence imaging was done using a Zeiss Axioscope 
II, with a Zeiss 40x or 100x Plan-Apochromat NA1.4 oil objective, a 
Hamamatsu Orca II digital camera, and Openlab software (Improvision).  
Spinning disk confocal images were taken with a Nikon Eclipse TE2000-U, 
Nikon Plan-Apo 60xA/N1.4 or Nikon Plan-Apo100x/N1.4 oil objectives, with 
Perkin-Elmer Ultraview LCI, a Hamamatsu 1394 ORCA-ER camera, and 
Perkin-Elmer Ultraview software.  
 
Statistics 
Error bars on graphs represent standard error of the mean values for a 
minimum of one hundred cells and a minimum of three independent 
experiments.  Two-tailed, unequal variance student T-tests were used to 
determine significance.   
 
Results 
PAFAH Ib α1 and α2 are Found on Early Sorting Endosomes and the 
Endocytic Recycling Compartment 
 The intracellular location of PAFAH Ib α1 and α2 has not been well 
documented.  One study found GFP-tagged α1 diffuse in the cytoplasm, in the 
nucleus, and on juxtanuclear structures that resemble the Golgi complex (358).  
We have confirmed this localization pattern in cells transfected with HA-
tagged α1 and α2 (259).  In addition, we found that α1-HA and α2-HA were 
located on peripheral cytoplasmic puncta that colocalized with the early 
endosome proteins EEA1 and GFP-Rab5 (Figure 4-1 A, B; 4-2 A).  At higher 
magnifications, the mosaic nature of this compartment was revealed as  
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Figure 4-1:  Localization of α1 to early and recycling endosomes.  (A) HA-
tagged α1 (anti-HA) was expressed and partially colocalized with the early 
sorting endosome protein GFP-Rab5 in BTRD cells.  Lower panel shows a 
higher magnification of the cell.  (B) Line fluorescence intensity plot of α1 and 
GFP-Rab5 from the merged confocal slice in A, line shown in merge.  (C) Cells 
expressing both α1-HA and GFP-Rab11 show α1 colocalizes to the ERC.  
Lower panel shows a higher magnification of the cell.  (D) Line fluorescence 
intensity plot of α1 and GFP-Rab11, from the line shown in the merged 
confocal slice of (C).  Scale bars = 10 µm. 
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Figure 4-2:  Localization of α1 and α2 to early but not late endosomes. 
Representative images of the localization the subunits are shown with either 
α1 or α2.  (A) HA-tagged α1 (anti-HA) was expressed and partially 
colocalized with the early sorting endosome protein EEA1 (anti-EEA1) in 
BTRD cells.  Box shows region in lower panel with magnified view of early 
sorting endosomes labeled with both α1-HA and EEA1.  Arrow indicates a 
tubule-projection seen with anti-HA but not anti-EEA1.  (B) Catalytically 
inactive and HA-tagged α1 S47A localizes to early sorting endosomes.  
(C) HA-tagged α2 was expressed and did not overlap with labeling for late 
endosomes, anti-CD63. 
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EEA1 was confined to the spherical domain whereas α1-HA could also be 
found on tubular extensions (Figure 4-2 A).  PAFAH Ib α1 and α2 have 
conserved lipase motifs, and changing the serine residues in these motifs (α1 
S47A; α2 S48A) renders the subunits catalytically inactive (318).  We found 
that α1 S47A and α2 S48A were still partially localized to EEA1-positive early 
sorting endosomes in transfected cells, demonstrating that catalytic activity is 
not required for organelle targeting (Figure 4-2 B; data not shown).   
In addition to peripheral early sorting endosomes, HA-tagged α1 and 
α2 were found on the centrally located ERC, as determined by colocalization 
with the ERC marker GFP-Rab11 (Figure 4-1 C, D).  Localization of α1 or α2 
on late endosomes/lysosomes was not observed (Figure 4-2 C).  
 
Overexpression of α1 or α2 Alters the Location of Endocytic Compartments 
 While α1 and α2 were found on early sorting endosomes and recycling 
endosomes, we observed that the distribution of early and late endosomes, but 
not recycling endosomes, was altered by overexpression (Figure 4-3).  Both 
early and late endosomes appeared to be dispersed to the periphery, similar to 
defects in dynein-dependent endosome transport to the centrosome (65, 66, 
349, 381).  The overexpression of α1 or α2 has been shown to affect LIS1-
dynein interactions by sequestering LIS1 away from dynein (337), resulting in 
dispersed membrane organelles labeled by wheat germ agglutinin (338).  
However, the exact endocytic organelles affected by this and the contribution 
of α1 and α2 catalytic activity was not explored.   
 To test whether this redistribution is dependent on α1 and α2 catalytic 
activity, LIS1 binding, or both, we expressed α1 S47A, α1 E38D (337), or the 
double mutant α1 S47A/E38D.  The overexpression of both catalytically active  
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Figure 4-3:  Overexpression of α1 or α2 redistributes early and late endosomes 
to the cell periphery.  (A) Wide-field images of untransfected BTRD cells side-
by-side with cells expressing either wild type α1, catalytic inactive α1 S47A, 
LIS1 binding mutant α1 E38D, or double mutant α1 S47A/E38D (HA-tagged) 
and co-labeled with early (EEA1), late (CD63) and recycling endosomes (GFP-
Rab11) markers.  * indicates transfected cells.  Scale bar = 10 µm.  
(B) Quantification of the percent of cells with endosomes, early (EEA1) or late 
(CD63), dispersed toward the cell periphery. (Quantification by Ina Chen) 
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and inactive α1 S47A resulted in a peripheral distribution of late and early 
endosomes, whereas—consistent with Ding et al. (338)—expression of α1 
E38D had normal endosome distribution.  Likewise, the LIS1-binding 
defective and catalytically inactive α1 S47A/E38D, showed normal 
distribution of early and late endosomes (Figure 4-3).  The endocytic recycling 
compartment, as seen by GFP-Rab11, appeared unaffected by the expression 
of α1 or the various α1 mutants. These overexpression results are also 
consistent with knockdown experiments (see below), indicating the expression 
levels of α1 and α2 impact the location of early endosomes. 
 
siRNA-Mediated Knockdown of α1 and α2 Alters the Localization of 
Endocytosed Transferrin and Delays Transferrin Recycling 
Previous studies have shown that PLA2 antagonists inhibit the 
trafficking of Tf through the endocytic recycling pathway (245).  To investigate 
the potential role of PAFAH Ib PLA2 subunits, α1 and α2, in endocytic 
recycling, siRNA-mediated knockdown was conducted with siRNAs targeting 
both α1 and α2.  A large assortment of cell lines was found to express both α1 
and α2, therefore it was necessary to transfect cells with an siRNA mixture to 
knockdown both proteins.  In BTRD cells, the mixed siRNAs reproducibly 
generated a >80% reduction in α1 and α2 levels (Chapter 2, Figure 2-9).   
Tf trafficking in cells with reduced α1 and α2 was monitored over a 
pulse-chase time course with FITC-Tf.  Within 5 min of endocytosis, the 
amount of FITC-Tf was equivalent between α1 and α2 knockdown and control 
cells (Figure 4-4 A, B), indicating that knockdown did not affect endocytosis.  
Within 15 min of FITC-Tf endocytosis, there was an apparent difference 
between knockdown and control cells.  In knockdown cells, the FITC-Tf was  
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Figure 4-4:  siRNA-mediated knockdown of α1 and α2 delays the recycling of 
transferrin.  BTRD cells were transfected with control or α1 and α2 siRNAs 72 
h before experimentation.  (A) Pulse-chase experiments were conducted with 
FITC-Tf in control and α1 and α2 siRNA-treated cells.  Cells were pulse-
labeled with FITC-Tf for 45 min, followed by chase in media containing 
unlabelled (non-fluorescent) Tf for 15 min.  Representative confocal images 
are shown for the indicated time points.  (B) Total FITC-Tf fluorescence was 
measured at 5 and 15 min after addition of FITC-Tf to the media (pulse).   
(C) At the indicated chase time points, transferrin fluorescence remaining in 
cells was quantified and is shown as a percent of the total transferrin 
fluorescence after 45 min pulse (maximum Tf fluorescence).  At 30 min,  
p < 0.05 by a T-test.  (D) The fluorescence intensity of the juxtanuclear, central 
FITC-Tf was measured at the indicated pulse and chase time points in control 
or α1 and α2 siRNA-treated cells.  n = 4, error bars = SEM. 
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clustered in a tight, central ERC-like location, with very few peripherally 
labeled endosomes (Figure 4-4 A, D).  This became more evident by 45 min 
pulse.  This distribution of FITC-Tf was also evident during chase of FITC-Tf 
out of the cells (Figure 4-4 A, D).  Additionally, during chase time points, α1 
and α2 knockdown cells appeared to retain FITC-Tf fluorescence over a longer 
period of time, indicating the recycling of FITC-Tf was slowed (Figure 4-4 A, 
C).   
 
Knockdown of α1 and α2 Alters the Distribution of Early and Late 
Endosomes But Not the Endocytic Recycling Compartment 
Since the distribution of FITC-Tf was affected by α1 and α2 
knockdown, and overexpression affects the distribution of endosomes, we 
wanted to address whether the physical location of endosomes was affected 
with the reduction of α1 and α2.  Therefore, we analyzed the distribution of 
early endosomes, late endosomes, recycling endosomes, and lysosomes in α1 
and α2 knockdown BTRD cells.  Endosomes labeled with EEA1, CD63, and 
Cathepsin D, but not GFP-Rab11, were more clustered in the cell center with 
reduced α1 and α2 (Figure 4-5).  To determine whether this phenotype was 
due to decreased α1 and α2 PLA2 activity or a consequence of reduced 
binding to LIS1, which regulates dynein activity (331, 340), we expressed 
RNAi-resistant versions of α1 wild type, catalytic inactive (α1 S47A), and LIS1 
binding mutants α1 E38D or α1 S47A/E38D in cells that were treated with α1 
and α2 siRNAs.  Cells expressing RNAi-resistant α1 or α1 S47A rescued the 
distribution of early and late endosomes, as well as lysosomes.  In contrast, 
cells expressing LIS1-binding mutant versions displayed similar phenotypes 
to α1 and α2 knockdown cells (Figure 4-6), suggesting that endosome  
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Figure 4-5:  Reduced levels of α1 and α2 redistributes early endosomes, late 
endosomes, and lysosomes to the cell center. Confocal images of early 
endosomes (EEA1), late endosomes (CD63), lysosomes (Cathepsin D), the 
transferrin receptor (TfR), or recycling endosomes visualized with expression 
of GFP-Rab11 in BTRD cells transfected with control RNA or siRNA targeting 
α1 and α2. 
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Figure 4-6:  Endosome positioning is altered in α1 and α2 knockdown cells 
due to lost interactions with LIS1.  (A) Confocal images of α1 and α2 siRNA-
treated BTRD cells transfected with RNAi-resistant α1, catalytic inactive α1 
S47A, LIS1 binding mutant α1 E38D, or double mutant α1 S47A/E38D.  Wild 
type α1 and catalytic inactive α1 S47A rescued endosome clustering seen with 
α1 and α2 knockdown, but LIS1 binding mutant (E38D) versions did not 
rescue changes in endosome distribution.  * indicates cells transfected with α1 
RNAi-resistant constructs, as determined by anti-HA staining.   
(B) Quantification of early and late endosome clustering in knockdown and 
RNAi-resistant α1 transfected cells as indicated.  n = 3-4, error bars = SEM. 
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clustering is a result of lost α1 and α2 interactions with LIS1. 
 This redistribution of endocytic markers could result from physical 
relocation of endosomes, mis-targeting of endocytic proteins, or enhanced 
fusion of early endosomes with late endosomes.  To determine whether the 
endosome markers still appropriately localize to distinct early and late 
endosome organelles in α1 and α2 knockdown cells, double- and triple-
labeling with Rab proteins was conducted.  The reduction of α1 and α2 levels 
did not affect the colocalization of EEA1 with GFP-Rab4 or GFP-Rab5 (Figure 
4-7).  Conversely, EEA1 did not localize to GFP-Rab7 or CD63 late endosomes 
(Figure 4-7 A; data not shown).  Additionally, CD63 did not colocalize with 
GFP-Rab4 (Figure 4-7 A) but did colocalize appropriately with GFP-Rab7 (not 
shown).   
 As a second test of endosome identity, we examined whether Tf is 
delivered to EEA1-labeled endosomes shortly after endocytosis.  Within 5 min 
of internalization from the plasma membrane, proteins arrive in EEA1-labeled 
early endosomes but are not yet sorted to the ERC or late endosomes (115).  
Control and α1 and α2 knockdown cells were immunostained for EEA1 to 
determine if FITC-Tf internalized for 5 min was localized with EEA1-labeled 
early endosomes.  In both control and α1 and α2 knockdown cells FITC-Tf 
colocalized with a subset of EEA1-labeled puncta.  In α1 and α2 knockdown 
cells, the majority of FITC-Tf was localized to central EEA1 puncta, indicating 
that Tf did reach early endosomes (Figure 4-7 C).  
 
Knockdown of α1 and α2 Inhibits Endosome Tubule Formation 
Early sorting endosomes and the ERC are complex tubulo-vesicular 
organelles.  At steady state, the tubular elements are difficult to image and  
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Figure 4-7:  Endosome identity is not affected by α1 and α2 knockdown.   
(A) Early endosome Rab4 tagged with GFP was expressed in control or α1 and 
α2 siRNA-treated cells and triple labeled to compare the localization with 
early endosome marker EEA1 and late endosome marker CD63 by confocal 
microscopy.  GFP-Rab4 labeled endosomes that contain EEA1, but not CD63, 
in control and knockdown cells.  Scale bars = 10µm.  (B) Early endosome GFP-
tagged Rab5 was expressed in control or α1 and α2 knockdown cells and co-
stained with anti-EEA1 antibodies.  GFP-Rab5 labeled endosomes that contain 
EEA1 in control and knockdown cells.  Scale bars = 10µm.  (C) BTRD cells 
treated with either control siRNA or α1 and α2 siRNA were exposed to FITC-
Tf at 4oC to allow binding to TfRs, then shifted to 37oC for 5 min to permit 
endocytosis and delivery to early endosomes.  Both control and knockdown 
cells show partial colocalization between FITC-Tf and anti-EEA1. 
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quantify, because they are highly dynamic.  However, the tubular domains of 
endosomes become greatly enhanced when treated with brefeldin A (BFA), an 
inhibitor of coated vesicle formation (382-384).  BFA provides a useful tool for 
investigating the molecular mechanisms required to make tubules.  For 
example, previous studies showed that PLA2 antagonists inhibit BFA-
stimulated endosome tubule formation (245).  Therefore, we asked if α1 and 
α2 are required for BFA-stimulated tubule formation by performing siRNA-
mediated knockdown experiments.  In control cells, early endosomes and the 
ERC labeled with FITC-Tf rapidly undergo extensive tubule formation 
following addition of BFA, whereas the endosomes in siRNA-treated cells 
displayed many fewer tubules (Figure 4-8).  Quantification of these results 
revealed that the extent of membrane tubule formation was reduced in 
knockdown cells (Figure 4-8 B). 
 
Overexpression of PAFAH Ib α1 or α2 Induces Endosome Tubule Formation 
To determine if, conversely, overexpression of α1 or α2 increased 
endosome tubule formation, Bret Judson, a former member of the Brown 
laboratory, measured the percentage of endosomes that had tubular 
morphology in transfected and non-transfected cells that had internalized 
TRITC-Tf for 45 min, which labels both early and recycling endosome 
compartments.  For these experiments, he primarily measured the peripheral 
endosomes, which correspond to early sorting endosomes.  Overexpression of 
wild type α1 or α2, caused peripheral endosomes to become more tubular.  
Long axis lengths of sorting endosomes in untransfected cells were 1.04 + 0.2 
µm versus 1.41 + 0.3 µm in transfected cells (Figure 4-9).  In addition, the 
percentage of total endosomes with tubules was increased (Figure 4-9 B).  This  
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Figure 4-8:  α1 and α2 knockdown inhibits BFA-stimulated tubulation of 
endosomes.  (A) Cells transfected with control RNA or siRNAs against α1 and 
α2 were incubated with FITC-Tf for 45 min to label all early sorting 
endosomes and the ERC, and then treated with BFA (5 µg/ml) in the 
continuous presence of FITC-Tf for the indicated times.  Scale bar = 10µm.   
(B) Magnified images of FITC-Tf-labelled endosomes in control and α1&2 
siRNA treated cells after 5 min of BFA treatment.  (C) Quantification of BFA-
stimulated tubulation in control and α1 and α2 siRNA treated cells.  n = 4, 
error bars = SEM. 
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Figure 4-9:  Overexpression of α2 induces endosome tubule formation.   
(A) Representative images of control HeLa cells and HeLa cells transfected 
with α2. Cells were incubated with Tf-TRITC for 45 min to label endocytic 
compartments.  (B) Fraction of total endosomes with tubules in untransfected 
cells or cells transfected with either α2 or catalytically inactive α2 S48A.  
(>2000 endosomes counted/condition).  Experimental results from Bret 
Judson. 
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tubule formation was dependent on catalytic activity because overexpression of 
a catalytic mutant (α2 S48A) did not result in an increase of tubulated 
endosomes. 
 
Overexpression of PAFAH Ib α1 or α2 Alters Trafficking Through the 
Endocytic Recycling Compartment  
To investigate whether the overexpression of α1 and α2 may enhance 
endocytic trafficking, we examined the effect of α1 or α2 overexpression on 
trafficking of Alexa 488-labeled Tf (Tf-488).  We overexpressed either wild 
type α1 or α2, constructs containing mutations in active site serines, or LIS1-
binding deficient mutants and followed Tf-488 during a pulse-chase time 
course.  Only α1 is shown and discussed here, as results for α1 and α2 were 
comparable.  Cells were incubated with media containing Tf-488 (pulse) for 45 
min followed by replacement of the media with unlabeled Tf (chase) for 40 
min.  The internalization of fluorescent Tf in 15 min was equivalent between 
control and all α1-overexpressing cells (Figure 4-10; 4-11 A).  Following a 45 
min pulse of Tf-488 in untransfected cells or cells transfected with LIS1-
binding mutants, α1 E38D or α1 S47A/E38D, Tf-488 was localized to puncta 
throughout the cell as well as clustered in the juxtanuclear ERC (Figure 4-10; 
4-11).  However, in cells expressing α1 wild type or α1 S47A, Tf localized only 
to puncta in the periphery.  Similarly, TfRs were found peripherally 
distributed in α1 or α1 S47A transfected HeLa cells but TfR distribution was 
not affected in cells expressing LIS1 binding mutant constructs (Figure 4-11 C).   
To compare Tf recycling, a chase with unlabeled Tf for 10, 20 min or 40 
min was conducted.  In control cells and cells expressing LIS1-binding mutant 
versions of α1, Tf-488 accumulated in the central ERC; and over the 40 min of  
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Figure 4-10:  Overexpression of α1 re-routes Tf and the TfR traffic from early 
endosomes, bypassing the central endocytic recycling compartment, back to 
the plasma membrane due to LIS1 binding.  HeLa cells were transiently 
transfected with α1-HA or α1 mutants and pulse-labeled with Alexa 488-Tf 
(Tf-488) for 15 and 45 min, followed by chase in transferrin-free media for 20 
or 40 min to observe transferrin internalization and recycling.   
Scale bar = 10µm. 
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Figure 4-11:  Overexpression of α1 changes the distribution of Tf and the TfR, 
and double mutant α1 S47A/E38D slows Tf recycling.  (A) The fluorescence 
intensity of Alexa 488-Tf was measured for pulse and chase time points in 
untransfected (control) HeLa cells and cells expressing indicated proteins.  α1 
S47A/E38D compared to control or α1 E38D is significantly different with p < 
0.0001 as analyzed by a T-test.  (B) Quantification of the percent of cells with 
central (ERC) Tf fluorescence after a 45 min pulse of Alexa 488-Tf (Tf-488).   
(C) Percent of cells with central Tf receptor (anti-TfR) fluorescence.  Anti-TfR 
was used without co-labeling with anti-HA, as the antibodies were both from 
mice.  Therefore, cell counts include both transfected and untransfected HeLa 
cells.  Error bars = SEM. 
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chase, Tf-488 signal was progressively lost due to the recycling of Tf out of the 
cell and its release into the medium (Figure 4-10).  The overexpression of α1 or 
α1 S47A did not have an effect on the kinetics of Tf recycling but rather 
affected the route of Tf, as fluorescent Tf never accumulated in the ERC 
(Figure 4-10; 4-11 A, B).  These results suggest that overexpression of α1 or α2, 
likely by disrupting LIS1 activation of dynein (337, 338), reduced the transport 
of Tf from peripheral early sorting endosomes to the central ERC, thus 
bypassing the ERC during the recycling to the cell surface.  The 
overexpression of α1 E38D also did not interfere with the recycling of Tf, since 
fluorescence of Tf-488 during chase time points was comparable to control 
cells (Figure 4-11 A).  There was, however, a noticeable difference in recycling 
kinetics with the double mutant α1 S47A/E38D.  During chase time points, α1 
S47A/E38D showed higher Tf-488 fluorescence in the cell, suggesting delayed 
recycling kinetics, compared to α1 E38D and control cells.  
 
Discussion 
These results reveal a novel mechanism for mediating endosome 
membrane trafficking and morphology with a new functional role for 
cytoplasmic PAFAH Ib α1 and α2.  Overexpression of α1 or α2 had three clear 
phenotypic consequences: 1) re-distribution of early and late endosomes 
toward the cell periphery, 2) stimulation of Tf/TfR export from early sorting 
endosomes to the plasma membrane, bypassing the ERC, and 3) stimulation of 
endosome tubule formation.  These phenotypes were opposite to effects seen 
with loss of α1 and α2: 1) re-distribution of early endosomes, late endosomes, 
and lysosomes to the cell center, 2) a delay in Tf recycling to the cell surface, 
and 3) inhibition of BFA-stimulated endosome tubules. 
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The altered organelle distribution observed by overexpression or 
knockdown of α1 and α2 could be explained by, respectively, increased or 
decreased interactions with LIS1.  This would affect the fraction of LIS1 
available to bind and activate dynein for minus end-directed microtubule 
transport (331, 337).  In effect, the overexpression or knockdown would 
decrease or increase, respectively, transport of endosomes and lysosomes 
towards the centrosome, which is a dynein-dependent function activated by 
LIS1 (65, 66, 360, 381).  Our results are in agreement with reports that 
overexpression of α1 and α2 affect LIS1 binding and regulation of dynein in 
endosome and lysosome transport (338).   
The effects of α1 and α2 overexpression and knockdown on Tf 
recycling may also be partially explained by interactions with LIS1.  Pulse-
chase experiments demonstrate that overexpression of wild type and 
catalytically inactive α1 and α2, prevent transport of Tf from peripheral early 
sorting endosomes to the ERC (step C in Figure 4-12) but not the release of 
internalized Tf from the cell.  These results strongly suggest that Tf was 
recycled directly from early sorting endosomes rather than from the ERC (step 
B of Figure 4-12).  In fact, a portion of the endocytosed membrane and 
receptors are normally recycled from early sorting endosomes directly back to 
the plasma membrane (143, 144).  This apparent re-routing of Tf and TfR did 
not occur with the overexpression of LIS1-binding defective constructs, 
strongly suggesting that Tf and TfR may be shuttled directly from early 
endosomes to the plasma membrane due to decreased dynein activation by 
LIS1.  This indicates that dynein activation by LIS1 is important for transport 
from early endosomes to the endocytic recycling compartment, a trafficking 
step that is dynein-dependent and membrane tubule-mediated (115, 350, 385).  
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Figure 4-12:  Diagram of the effect of α1 and α2 overexpression and 
knockdown on endosome distribution and trafficking.  (A) Normal trafficking 
routes of endocytosed cargo are shown.  Step A: cargo is endocytosed at the 
plasma membrane and delivered to early sorting endosomes.  Step B: A 
portion of cargo to be recycled is delivered from early endosomes to the 
plasma membrane.  This transport involves kinesin motors. The position of 
early and late endosomes in the cell as well as the transport of cargo destined 
for degradation (non-recycled) are both dynein-dependent.  Step C: The 
predominant route of recycled cargo, such as transferrin, is from early 
endosomes to the centrally located endocytic recycling compartment.  This is a 
dynein and membrane tubule-mediated process.  Red arrows depict tubule-
mediated trafficking.  Recycled cargo then travels as in Step D, from the ERC 
to the plasma membrane.  This step uses kinesin motors. (B) The effects seen 
with knockdown of α1 and α2 on endosomes.  Early and late endosomes 
cluster in the center of the cell via a LIS1-mediated effect, presumably through 
the activation of dynein motors.  Additionally, knockdown delays recycling of 
Tf from the center of the cell, slowing step D.  (C) The effects of α1 or α2 wild 
type overexpression are depicted.  Early and late endosomes were seen in the 
cell periphery due to LIS1 binding, which likely prevented activation of 
dynein.  This would inhibit step C and decrease cargo recycling at step D, 
increasing the amount of cargo recycled through step B. 
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These results also are reminiscent of dynein inactivation by the overexpression 
of dynamitin, which also shifted the route of Tf recycling directly from 
peripheral sorting endosomes but did not affect the kinetics of recycling (349).  
The binding of LIS1 by excess α1 or α2 (from overexpression) would, in effect, 
decrease the activation of dynein-mediated transport of cargo, including Tf 
transport from the early sorting endosomes to the ERC (Figure 4-12 C).  
The catalytically inactive LIS1-binding mutant, α1 S47A/E38D, did not 
re-route Tf but did delay Tf recycling compared to control cells and α1 E38D 
overexpressing cells.  This catalytically inactive mutant (α1 S47A/E38D) may 
act as a dominant negative, which has been suggested by recent studies (259).  
Catalytically inactive subunits may dimerize with endogenous subunits, 
creating inactive, ‘poisoned’ dimers.  A dominant negative effect by the 
catalytic mutant is consistent with knockdown experiments, which also 
showed a delay in Tf recycling.  If catalytically inactive α1 (S47A) or α2 (S48A) 
act as dominant negatives, one would predict that the α1 S47A would also 
delay Tf recycling.  A possible explanation to this apparent inconsistency is 
depicted in Figure 4-12: α1 and α2 are important for the membrane trafficking 
from early endosomes to recycling endosomes (step C) and/or from the ERC 
to the plasma membrane (step D) but not necessarily in the ‘short’ recycling 
pathway directly from the early sorting endosomes to the plasma membrane 
(step B).  This is an appealing possibility that fits well with our observations.  
The overexpression of α1 or α2, which are able to bind LIS1, appear to 
dramatically inhibit dynein-dependent function, blocking early to recycling 
endosome transport (step C) and re-routing Tf to recycle from early 
endosomes to the plasma membrane (step B).  Therefore, no apparent 
dominant negative phenotype would be seen, as the trafficking steps 
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regulated by α1 and α2 would already be blocked by reduced dynein 
function.  This suggests that α1 and α2 are important for transport from early 
endosomes to the ERC (step C) and/or from the ERC to the plasma membrane 
(step D).   
Previous studies have shown that BFA enhances endosome membrane 
tubule formation (382, 384), effects that are inhibited by PLA2 antagonists 
(245).  Consistent with this idea, we found that overexpression of catalytically 
active, but not inactive, α1 or α2 increased the number of tubulated peripheral 
endosomes.  Additionally, α1 and α2 knockdown inhibited Tf-labeled 
endosome tubules.  Changes in membrane tubule formation seen in 
overexpression and knockdown, can be explained by the direct membrane 
altering action of PAFAH Ib PLA2 subunits, α1 or α2, as catalytically inactive 
forms of α1 or α2 (α1 S47A and α2 S48A) did not increase endosome 
membrane tubules.  The hydrolytic activity of PAFAH Ib α1 or α2 may 
contribute to the formation of membrane tubules by removal of the acyl chains 
from the sn-2 position of phospholipids, resulting in a shift from cylindrical or 
cone shaped phospholipids to inverted-cone shaped lysophospholipids (242).  
Localized accumulation of lysophospholipids creates tighter packing of the 
acyl chains in one leaflet of the endosome membrane bilayer, resulting in 
outward curvature of the membrane that could then grow into a tubule (198, 
217).  Alternatively, the lipid-modifying activity of α1 and α2 may feed into 
lipid-modifying pathways that can either directly affect membrane curvature 
or indirectly by recruiting proteins that bend membranes.   
The exact physiological role of PAFAH Ib has been unclear.  Studies 
have suggested various roles for PAFAH Ib in regulating LIS1/β and its 
interactions with dynein (331, 337, 338).  To identify other functional roles for 
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PAFAH Ib, researchers have produced α1 and α2 knockout mice (326, 330).  
Surprisingly, male and female α1-/- and female α2-/- mice were grossly 
normal, but male α2-/- mice were infertile with spermatogenesis defects.  
These defects appeared at earlier stages of meiosis in double knockout mice. 
Although PAF levels have been shown to influence sperm function (386, 387), 
the results of knockout studies, and lack of observable phenotypes, cause one 
to wonder about the exact physiological role of PAFAH Ib in other tissues.  Of 
course, there may be functional redundancy, as other enzymes could 
compensate for the absence of α1 and α2 in the knockout mice.   
There is growing evidence that cytoplasmic PLA2 enzymes contribute 
to the formation of membrane tubules and regulate trafficking for other 
organelles (78, 244, 246, 249).  In the past year, three phospholipases have been 
shown to be involved in Golgi structure and function.  The cytoplasmic Ca2+-
dependent enzyme, cPLA2α, was shown to be recruited to the Golgi following 
an increase in secretory load and to enhance intra-Golgi membrane tubules 
that facilitate anterograde transport through the Golgi stack (256).  cPLA2α, 
was also found to be required for export of junctional proteins in polarized 
endothelial cells (258).  iPLA1γ, was shown to be required for retrograde 
trafficking from the Golgi (260).  Finally, in other studies, we have found that 
PAFAH Ib α1 or α2 are also localized to the Golgi complex where they 
mediate tubule formation and secretory trafficking (259).  These results, along 
with studies here, establish that α1 or α2 function at multiple organelles.   
In summary, our studies identify a specific cytoplasmic PLA2, PAFAH 
Ib, that is capable of inducing membrane tubule formation and altering 
endocytic membrane trafficking pathways.  Furthermore, these results 
demonstrate a physiological role for PAFAH Ib in mediating intracellular 
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membrane trafficking.  Future research should address how PAFAH Ib 
selectively interacts with endosome and Golgi membranes, and if it interacts 
with other molecules, e.g., Rabs, sorting nexins, phosphoinositides, to facilitate 
efficient endosomal sorting.  Nevertheless, this work and the recent work of 
others demonstrate the importance of lipid-modifying enzymes in both 
secretory and endocytic trafficking. 
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CHAPTER 5 
 
Gβ1γ2 Activates Phospholipase A2-Dependent Golgi Tubule Formation 
 
Abstract 
 Heterotrimeric G proteins transduce the ligand binding of heptahelical 
transmembrane G protein coupled receptors into a variety of intracellular 
signaling pathways.  Recently, heterotrimeric Gβγ subunit signaling at the 
Golgi complex has been shown to regulate the formation of transport carriers 
that deliver cargo from the Golgi to the plasma membrane.  This regulation 
has been shown to increase protein kinase D-activated fission of TGN 
membranes.  While several components of this signaling have been identified, 
the machinery directly involved in membrane fission as well as the proteins 
required in the initial formation of these transport carriers are unknown.  Here 
we provide evidence that Gβ1γ2 signaling also stimulates Golgi membrane 
tubule formation using a reconstitution assay with isolated Golgi complexes.  
We show that an inhibitor of Gβγ activation of PLA2 enzymes inhibits in vitro 
Golgi membrane tubulation.  Additionally, purified Gβγ protein stimulates 
membrane tubules in the presence of low (sub-threshold) cytosol 
concentrations, and this stimulation of Golgi membrane tubules was repressed 
when PLA2 enzymes were inhibited with ONO-RS-082.  These studies indicate 
that Gβ1γ2 signaling activates PLA2 enzymes required for Golgi membrane 
tubule formation. 
 
Introduction  
 Cargo transport from the trans Golgi network (TGN) to the plasma 
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membrane involves both membrane bound vesicles and membrane tubules. 
Cargo destined for the plasma membrane, such as VSV-G, has been visualized 
to travel from the TGN in long, thin membrane-bound transport carriers (108, 
181, 186, 189).  Additionally, vesicle markers have been shown to partially 
colocalize with these membrane tubule extensions, from which vesicles may 
bud (186, 189, 388).  The formation of vesicular and tubular transport carriers 
from the mammalian Golgi complex require regulation for precise spatial and 
temporal trafficking within a cell.  The regulation of vesicular transport 
carriers by small GTPases, such as Arf1, Arls, and Rabs, as well as kinases, 
including Src family members, LIM kinase, protein kinase C (PKC), and 
protein kinase D (PKD) has been examined (71, 97, 119, 389-391).  The outward 
budding of a nascent vesicle initially requires positive membrane curvature 
that is also necessary for forming membrane tubule carriers.  However, little is 
known about the mechanisms that regulate the positive curvature and the 
formation of membrane tubules at the TGN.  
A series of pharmacological studies using phospholipase A2 (PLA2) 
antagonists indicate that phospholipases are an essential component of 
membrane tubule formation (78, 244, 249, 364).  Recent studies have since 
identified specific phospholipase (PLA) enzymes that contribute to different 
levels of Golgi membrane tubule formation: cPLA2α, iPLA1γ, and platelet 
activating factor acetylhydrolase Ib (256, 258-260).  These phospholipases have 
partially overlapping function and contribute to distinct aspects of Golgi 
structure and trafficking.  However, it is not known how these PLA enzymes 
are individually regulated, nor is it understood how membrane tubules in 
general are regulated.   
The large, heterotrimeric G protein family has been implicated in the 
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regulation of Golgi trafficking and architecture (392-397).  Additionally, 
previous pharmacological studies suggest that heterotrimeric G protein 
signaling activates PLA2 enzymes involved in Golgi membrane tubule 
formation (362).  Heterotrimeric G proteins are composed of α, β, and γ 
subunits, each of which exists in a variety of isoforms. A trimer of Gαβγ 
associates with transmembrane G protein coupled receptors (GPCRs).  In an 
inactive state, the Gα subunit binds to GDP and the Gβγ subunits, yielding a 
Gαβγ trimer, which is associated with GPCRs.  Upon GPCR activation, a 
conformational change triggers the alpha subunit to exchange GDP for GTP.  
This switch leads to dissociation of Gαβγ from the GPCR and dissociation of 
Gα from Gβγ, each of which is able to stimulate respective signaling cascades.  
Golgi structure and vesicle budding have been shown to be regulated 
by heterotrimeric G proteins, composed of various combinations of Gα, Gβ 
and Gγ subunit isoforms.  Early studies with ilimaquinone (IQ), a metabolite 
of marine sponges that vesiculates the Golgi complex, revealed a role for Gαs 
and Gαi-3 as well as Gβγ subunits at the Golgi (392, 394, 396, 398).  Gαi-3 and 
Gαq have also been implicated in the control of Golgi architecture and 
trafficking (395).  Specific Gβγ subunits Gβ1γ2 and Gβ2γ3, upon 
overexpression in mammalian cells, dramatically affect Golgi membrane 
structure and alter trafficking, likely through activation of PKCη and PKD at 
the TGN (392, 397).  The activation of PKC and, subsequently, PKD is 
important for the fission of vesicles at the TGN, and a kinase dead version of 
PKD (PKD-KD) has been shown to cause dramatic tubulation of the TGN 
(399).  Additionally, recent studies suggest that particular Gβγ isoforms are 
capable, upon GPCR stimulation, of translocating from the plasma membrane 
to the Golgi complex, where the Gβγ may trigger vesiculation of the Golgi 
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complex as well as increased transport (400, 401).  The localization of Gβ1γ2 
specifically to the Golgi complex resulted in fragmentation of the Golgi and 
TGN, and inactivation of endogenous Gβγ significantly affected secretory 
trafficking (393). 
In addition to roles in stimulating vesiculation, Gβγ has been implicated 
in regulating brefeldin A (BFA)-stimulated membrane tubules.  Golgi and 
endosome membrane tubules stimulated by BFA were inhibited by the 
biscolaurine alkaloid isotetrandrine (ITD) (362), an inhibitor of Gβγ-mediated 
PLA2 enzyme activation (402-404).  This membrane tubule inhibition by ITD is 
believed to be an effect of preventing activation of PLA2 enzymes through yet 
unknown Gβγ subunits.  Put together, it is likely that Gβγ simultaneously 
activates pathways that promote PLA2 enzyme activity to generate positive 
curvature (for both membrane tubules and vesicle formation) as well as 
activate machinery for vesicles fission.  
 Reported here is the use of a cell free reconstitution assay (405) to 
further test the idea that a Gβγ signaling pathway can activate PLA2-
dependent membrane tubule formation.  This method permits direct 
examination of individual components for contributions to Golgi membrane 
tubule formation.  
 
Methods and Materials 
Reagents 
Sprague-Dawley male rats were obtained from Charles River Breeding 
Laboratories, Inc.  Isotetrandrine (ITD) and ONO-RS-082 (ONO) were 
purchased from BioMol Research Laboratories, Inc.  Recombinant Gβ1γ2 
provided by our collaborator Dr. J. Garrison (University of Virginia Health 
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Sciences, Charlottesville, VA).   
 
Golgi Complex Isolation 
 Intact Golgi complexes from rat liver can be enriched following 
procedures described in (62).  A male Sprague-Dawley rat of 100-150 g was 
euthanized with CO2, and the liver was immediately removed and kept on ice.  
The rest of the procedure was performed at 4oC and on ice.  The liver was 
rinsed with ice-cold homogenization buffer (0.25 M sucrose, 10 mM Tris, pH 
7.4) until clear.  The liver was minced until fine with a razorblade and any 
connective tissue removed.  The pureed liver was weighed, and 
homogenization buffer was added to yield 20% weight/volume suspension.  
The suspension was passed through a Balch/Rothman homogenizer with a 
0.2460-inch ball bearing four times.  The resulting homogenate was spun in a 
SS-34 at 5,000 rpm (3,000 x g) for 10 min at 4oC to pellet nuclei and any 
unruptured cells.  The post-nuclear supernatant was then mixed with an equal 
volume of 2.3 M sucrose (10 mM Tris, pH 7.4), resulting in a final 1.4 M 
sucrose concentration, and 15 mL was added to the bottom of Beckman SW28 
ultracentrifuge tubes (38 mL capacity).  This was overlaid with sucrose step 
gradients (containing 10 mM Tris, pH 7.4) as follows: 8 mL 1.2 M sucrose, 8 
mL 1.0 M sucrose, 4 mL of 0.9 M sucrose, and 3 mL of 0.8 M sucrose.  The 
gradients were spun at 25,000 rpm (90,000 x g) in a Beckman SW28 rotor for 
2.5 h with no brake at 4oC.  Golgi membranes were collected with a Pasteur 
pipette at the 1.0 M/0.9 M interface and frozen in aliquots at -80oC.    
 
Preparation of Bovine Brain Cytosol 
 Bovine brain cytosol was prepared as described by (369).  The protease 
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stock solutions were prepared fresh as follows: 10 mg/mL 
phenylmethylsulfonyl fluoride (PMSF, 500x) in isopropanol, 1 mg/mL 
pepstatin A in methanol (18250x), 1 mg/mL aprotinin in water (625x), 50 
mg/mL 1, 10 phenantholine in ethanol (625x), 0.25 mg/mL leupeptin in water 
(625x).  Ethylene glycol tetraacetic acid (EGTA) was dissolved in water and 
solubilized with the addition of NaOH, for a final 0.38 g/mL solution.   
Fresh calf brains were obtained from a slaughterhouse and 
immediately put into 4oC buffer of 320 mM sucrose, 25 mM Tris, pH 7.4 and 
kept on ice for transport.  All procedures where done at 4oC and on ice as 
much as possible.  Meninges and blood vessels were removed and then brain 
tissue was coarsely chopped with a razorblade in a small amount of 
homogenization buffer, which contains: 25 mM Tris, 500 mM KCl, 250 mM 
sucrose, 1 mM dithiothreitol (DTT), 2 mM EGTA, pH 7.4 with 2 µg/mL 
aprotinin, 0.5 µg/mL leupeptin, 2 µM pepstatin A, 0.5 mM 1, 10-
phenanthroline, and 1 mM PMSF.  The minced brain was mixed with 2.5 times 
the weight (g) in volume (mL) of homogenization buffer and homogenized in 
a Waring blender for 30 sec two times on high.  Homogenized material was 
then spun in a GSA rotor at 9,000 rpm (13,000 x g) for 30 min at 4oC.  The 
supernatant was collected, PMSF was added to a final 1x concentration, and 
was then spun in a Type 35 rotor at 35,000 rpm (143,000 x g) for 2.25 h at 4oC.  
The supernatant was collected and more (1x) PMSF was added.  Over an hour, 
1.5 times the volume was added of saturated ammonium sulfate, pH 8.0 at 4oC 
for a final 60% ammonium sulfate, and then mixed for an additional hour at 
4oC.  The solution was then spun in a GSA rotor at 8,000 rpm (11,555 x g) for 
45 min at 4oC.  The supernatent was discarded, and each pellet was 
resuspended in 10 mL of dialysis buffer (25 mM Tris, 50 mM KCl, pH 8.0) 
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containing 0.5 mM DTT and (1x) protease inhibitors.  This suspension was 
placed into molecular weight 14 kDa cutoff dialysis tubing and placed into 
dialysis buffer + DTT for 1 h at 4oC, then dialyzed overnight in dialysis buffer 
(without DTT) at 4oC.  Dialysate was collected and PMSF added (to 1x), then 
spun in a Ti 50.2 rotor for 1 h at 45,000 rpm (90,000 x g) at 4oC.  The 
supernatant (BBC) was then collected, additional PMSF added and frozen in 
aliquots at -80oC.    
 
In Vitro Golgi Tubulation Assays 
In vitro Golgi tubulation assays were preformed as described in Banta 
et al (369).  All frozen reagents were rapidly thawed at 37oC and then kept on 
ice until use.  Gβγ was in the following buffer: 20 mM Tris base, pH 8.0, 1 mM 
EDTA, 1 mM DTT, 150 mM NaCl, and 0.1% Chaps (w/v).  BBC was spun in a 
TLA 100.3 rotor at 70,000 rpm for 20 min to remove precipitate.  Reaction 
mixtures containing BBC, purified protein, and/or inhibitors mixed with 
tubulation assay buffer (50 mM KCl, 1 mM MgCl2, 25 mM Tris, 10 mM HEPES, 
pH 7.4) and ATP (final 50 µM) were prepared as indicted in the results.  Golgi 
aliquots and reaction mixtures were prewarmed to 37oC for 15 min, after 
which the reaction mix was gently mixed 1:1 into the Golgi aliquots, and then 
incubated for 15 min at 37oC.  Ten microliters of each sample was spotted onto 
Formvar- and carbon-coated EM grids for 15 min, followed by staining 3 times 
for 4 sec with 2% phosphotungstic acid, pH 7.2.  Grids were stored in the dark 
until viewing by a FEI Morgagni 268 transmission electron microscope.  Upon 
viewing, Golgi were scored as tubulated or not tubulated, based on the 
presence of one or more membrane tubule (60-90 nm diameter) extensions.   
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Results 
A preparation of bovine brain cytosol (BBC) stimulates Golgi 
membrane tubules in a reconstitution assay (369), which can be inhibited by 
PLA2 inhibitors (78).  Here we describe the use of this in vitro reconstitution 
assay to assess the contribution of Gβ1γ2 and subsequent stimulation of PLA2 
enzymes to the formation of Golgi membrane tubules. 
 
Isotetrandrine Inhibits Cytosol-Stimulated Golgi Membrane Tubules In Vitro 
 Previous studies have shown that ITD inhibits BFA-stimulated Golgi 
membrane tubules in mammalian cells (362).  To determine if ITD similarly 
inhibits cytosol-stimulated Golgi tubules in vitro, we tested a range of ITD 
concentrations with varying BBC concentrations.  ITD exhibited a dose-
dependent inhibition of BBC-stimulated membrane tubules and showed a 
positive correlation between concentration of cytosol and the IC50 for 
membrane tubule inhibition (Figure 5-1).  This IC50 of membrane tubule 
inhibition is dependent on the individual preparation of BBC, as there is 
natural variation between different preparations of BBC.  We found an IC50 
range from 25-100 µM with cytosol concentrations that achieve maximum 
number of tubulated Golgi.  Therefore, for each BBC preparation, the 
appropriate IC50 was determined before further experimentation.  
 
Isotetrandrine Inhibits Golgi-Associated Components 
 The exact target of ITD is unknown (402-404), therefore we tested 
whether the target of ITD was cytosolic or membrane-associated.  The extent 
of Golgi membrane tubule inhibition was compared between ITD addition to 
the Golgi membranes themselves—presumably inhibiting a protein directly
 179 
Figure 5-1:  Dose-dependent inhibition of cytosol-stimulated Golgi membrane 
tubules.  (A) Example negative stain electron micrographs of tubulated and 
non-tubulated Golgi from the in vitro reconstitution assay.  Bovine brain 
cytosol (BBC, 1.5 mg/mL) was incubated with the indicated concentration of 
ITD and added to isolated Golgi complexes. Control Golgi were incubated 
with 0.2 mg/mL BSA.  Scale bars = 500 nm.  (B) Quantification of the percent 
of Golgi complexes with membrane tubules, normalized to the maximum 
percent of Golgi with tubules in the presence of each BBC concentration 
shown.  Averages are shown from minimum of 3 replicates, error bars = SEM. 
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associated with the membranes—versus ITD addition to the cytosol—
inhibiting a cytosolic target.  Either the BBC or Golgi membranes were 
pretreated with isotetrandrine, and then combined.  ITD was more efficacious 
when Golgi membranes were pretreated, consistent with the idea that ITD 
inhibits a Golgi-associated target (Figure 5-2). 
 
Gβ1γ2 Rescues ITD Inhibition 
The pharmacological effect of ITD is to inhibit Gβγ activation of PLA2 
enzymes (402-404).  To determine if ITD inhibits a pathway stimulated by Gβγ, 
as suggested by the previous pharmacological studies, Gβ1γ2 was added to 
the ITD-treated tubulation mixture and tested for its ability to stimulate Golgi 
membrane tubules.  BBC-stimulated Golgi tubulation was inhibited to near-
background levels by ITD (Figure 5-3).  Addition of increasing amounts of 
purified Gβ1γ2 protein to Golgi membranes treated with 25 µm ITD resulted 
in nearly complete restoration of membrane tubule formation to control levels 
(Figure 5-3).   
 
Gβ1γ2 Stimulates Golgi Membrane Tubules 
ITD inhibition of cytosol-stimulated Golgi membrane tubulation could 
be rescued by addition of purified Gβ1γ2, therefore we wanted to address 
whether Gβγ itself could stimulate membrane tubules in the reconstitution 
assay.  Since Gβγ contains a myristoylated tail and is soluble in low 
concentrations of CHAPS, we first tested the affect of the Gβγ buffer on Golgi 
membranes and found no effect (Figure 5-4 A).  Of the various Gβγ isoforms 
Gβ1γ2 was selected, as it is the most abundant isoform in bovine brain and has 
been shown previously to affect Golgi architecture and trafficking (393, 397). 
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Figure 5-2:  ITD inhibits Golgi-membrane associated proteins.  Various 
concentrations of ITD were either pre-incubated at 37oC for 15 min with BBC 
or Golgi membranes before combining the cytosol and Golgi, followed by 
further incubation at 37oC for 15 min.  (A) Representative negative stain Golgi 
treated with ITD, which was pre-incubated as labeled.  Scale bars = 500 nm.  
(B) Quantification of the percent of Golgi with membrane tubules, normalized 
to BBC alone (1.5 mg/mL).  ITD concentrations shown are the final 
concentration after mixing the Golgi and cytosol.  Error bars = SEM. 
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Figure 5-3:  Gβ1γ2 rescues ITD inhibition of cytosol-stimulated Golgi 
membrane tubules.  Quantification of the fraction of Golgi with tubules, 
relative to the maximum percent of Golgi with tubules seen with BBC (1.5 
mg/mL) alone.  Final concentrations (after mixing the pre-incubated Golgi 
and cytosol) are shown for purified Gβγ.  ITD final concentration was 25 µM.  
Error bars = SEM. 
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Figure 5-4:  Gβ1γ2 stimulates cytosol-dependent Golgi membrane tubulation.  
(A) Representative EM micrographs of Golgi from the reconstitution assay. 
Golgi were treated with BBC (1.5 mg/mL), a BSA control (0.2 mg/mL), Low 
BBC (0.15 mg/mL), or Low BBC + Gβ1γ2 (0.5 µg/mL Gβγ).  Each condition 
was in the presence of the Gβγ buffer.  Scale bar = 500 nm.  (B) Quantification 
of the percent of Golgi with membrane tubules, normalized to the maximum 
amount of tubulated Golgi with BBC (1.5 mg/mL).  Gβ1γ2 purified protein 
alone does not stimulate Golgi membrane tubules above background levels 
(no BBC control).  In the presence of low cytosol concentrations (Low BBC 0.15 
mg/mL), the addition of Gβ1γ2 stimulates membrane tubules.  Error  
bars = SEM. 
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 Gβγ, when added alone to Golgi membranes, was insufficient to 
stimulate membrane tubules above background (Figure 5-4).  Either Gβ1γ2 
does not stimulate membrane tubules or a cytosolic component (e.g. a PLA2) is 
required to induce membrane tubule formation.  Near background levels of 
membrane tubule formation are seen with low concentrations of BBC (sub-
threshold levels), which can be used in combination with other factors that 
promote membrane tubule formation to achieve maximum Golgi membrane 
tubules (249).  Therefore we tested whether Gβγ signaling requires a cytosol 
component by adding Gβγ to sub-threshold cytosol levels.  Indeed, we found 
that the addition of Gβ1γ2 in increasing amounts stimulated the formation of 
membrane tubules in the presence of low BBC (Figure 5-4).   
   
Gβ1γ2 -Stimulated Golgi Membrane Tubules are PLA2 Dependent 
 The above studies show that BBC contains a component that is 
stimulated by Gβ1γ2, likely a protein downstream of the target of ITD.  
Previous studies have demonstrated that BBC-stimulated Golgi membrane 
tubules require PLA2 enzyme activity (244), and ITD is suggested to inhibit 
Gβ1γ2 activation of PLA2 enzymes (406), so we tested whether Gβ1γ2-
stimulation of membrane tubules also requires PLA2 activity.  To examine this, 
a PLA2 enzyme antagonist documented to inhibit Golgi membrane tubules, 
ONO-RS-082 (244), was pre-incubated with cytosol for 15 min prior to 
addition with Golgi pre-incubated with Gβ1γ2.  The results showed that 
addition of Gβ1γ2 to low cytosol was able to stimulate Golgi membrane 
tubules, but Gβ1γ2 did not stimulate membrane tubules when cytosol was 
pretreated with ONO (Figure 5-5).  These results indicate that Gβ1γ2 requires 
PLA2 activity found in BBC to stimulate Golgi membrane tubules. 
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Figure 5-5:  Gβ1γ2 stimulation of Golgi membrane tubules is PLA2 activity 
dependent.  BBC (1.5 mg/mL) was pre-incubated with the PLA2 inhibitor 
ONO (at final concentration of 25 µM) at 37oC for 15 min, followed by the 
addition of Gβ1γ2 purified protein (final concentration of 0.4 µg/mL) to BBC 
before combining the cytosol and Golgi, and additional incubation at 37oC for 
15 min. Low BBC was 0.15 mg/mL and the BSA, as a negative control, was at 
a final 1 mg/mL concentration.  (A) Representative negative stain Golgi 
treated with ONO and Gβ1γ2 as labeled.  Scale bars= 500 nm.   
(B) Quantification of the percent of Golgi with membrane tubules, normalized 
to BBC alone (1.5 mg/mL).  Error bars = SEM. 
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Discussion 
 Here we provide in vitro evidence that heterotrimeric G protein 
subunits Gβ1γ2 stimulate Golgi membrane tubule formation, which is 
dependent on PLA2 activity.  Until now, the identified role of Gβ1γ2 at the 
Golgi complex has been limited to membrane fission in the generation of TGN 
vesicles.  This work is consistent with the hypothesis that Gβγ subunits are 
additionally important for activation of PLA2 enzymes that stimulate 
membrane tubule formation.   
Previous studies using the inhibitor ITD implicated Gβγ signaling in the 
regulation of PLA2 enzymes.  ITD has been used to inhibit inflammatory 
signaling, by decreasing Gβγ activation of PLA2 enzymes (404).  More recent 
studies show ITD inhibition of BFA-stimulated Golgi membrane tubule 
formation, suggesting a broader role of Gβγ regulation of PLA2 enzymes (362).  
Here we further explore the hypothesis that ITD inhibits Gβγ activation of 
PLA2 enzymes involved in the formation of Golgi membrane tubules, using an 
in vitro reconstitution assay.  We find that ITD inhibits BBC-stimulated 
membrane tubules from isolated Golgi complexes.  This inhibition can be 
rescued by the addition of purified Gβγ subunits, further supporting the 
notion that ITD inhibits a Gβγ signaling pathway.      
 Heterotrimeric Gβγ subunits have recently been shown to localize to 
the Golgi complex upon GPCR stimulation (393, 401, 407).  Once localized to 
the Golgi complex, Gβ1γ2 stimulates a signaling cascade that increases the 
TGN diacylglycerol levels necessary for the recruitment of PKD.  Upon 
reaching the Golgi, PKD is subsequently activated by PKCη, leading to 
phosphorylation of PI4KIIIβ and ceramide transfer protein (CERT).  This 
ultimately leads to enhanced fission and transport of cargo (222, 392, 393, 408, 
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409).   
Τhis signaling cascade includes factors, such as PKD, which have been 
implicated in vesicle fission (399, 410).  However, the current model does not 
address how the initial positive curvature to form vesicles and membrane 
tubules is generated to promote the increase in cargo transport upon GPCR 
stimulation.  Increased transport upon Gβγ signaling at the Golgi can be 
prevented by inactivation of PKD (397).  This inhibition of PKD kinase activity 
results in the exacerbation of long and persistent TGN membrane tubules 
(399).  These results indicate that the machinery involved in the outward 
bending of Golgi membranes is activated, but the subsequent fission is 
prevented.   
The TGN membrane tubules seen with PKD inactivation can be 
inhibited by the PLA2 inhibitor ONO (250).  ONO prevents the formation of 
new PKD kinase dead (PKD-KD) TGN tubules, decreases the number of TGN 
tubules containing ts045 VSV-G, and inhibits the transport of ts045 VSV-G 
from the TGN to the plasma membrane (250).  Consistent with this, the 
formation of Gβγ-stimulated tubules was sensitive to ONO inhibition when 
added to BBC.  This suggests that PLA2 enzyme activity present in the cytosol 
is required for Gβ1γ2 stimulation of tubules, which are likely stimulated 
upstream of PKD.  While it is possible that a separate signaling pathway 
regulates the formation of membrane tubules, it is conceivable that 
stimulation of both positive curvature for outward budding and negative 
curvature for fission are interconnected signaling pathways activated by Gβγ.   
The results presented here suggest the latter: Gβγ stimulates the outward 
curvature of Golgi membranes through PLA2 activation as well as PKD-
dependent fission.   
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Specific PLA2 enzymes cPLA2α and PAFAH Ib are implicated in the 
formation of Golgi membrane tubules and TGN to plasma membrane 
transport (256, 258, 259).  cPLA2α has been shown to be important for Golgi 
membrane tubule formation (256) and has been implicated in the transport of 
tight junction proteins to the plasma membrane (258).  Additionally, PAFAH 
Ib has been shown to affect the localization of PKD to the TGN and VSV-G 
kinetics from the Golgi to the plasma membrane (259).  It will be interesting in 
the future to determine whether these specific PLA2 enzymes, or unidentified 
PLA enzymes, are part of the Gβγ signaling pathway at the Golgi and how 
they are interconnected with PKD-activated fission to generate transport 
carriers.   
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